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ALTERATION OF DNA – TRANSCRIPTION FACTOR INTERACTIONS 
FOLLOWING CHROMIUM EXPOSURE 
 
Chairperson:  Dr. Kent Sugden  
 
  The effect of 8-oxoguanine in the consensus sequence of κB DNA on the binding 
affinity of p50BD was determined using a 22-mer and a 30-mer double-stranded DNA 
oligonucleotide containing the NF-κB binding site.  The addition of a carboxyl moiety at 
position 8 on guanine (creating 8-oxoguanine) was observed to change the binding 
affinity of the transcription factor for the κB DNA sequences at each modified guanine 
site.  The protocol used a p50 binding domain protein (residues 23 to 366 from the p50 
protein) and a p50 mutant protein with a single amino acid mutation of the wild type 
histidine 67 to alanine 67.  Both proteins were cloned as N-terminal his6-tagged proteins.  
These proteins were expressed and purified as active proteins.  It is known that reduction 
of chromium(VI) to chromium(III) creates species such as chromium(V) and 
chromium(IV) which interact with and damage DNA.  An oxidative event, such a 
chromium(VI) reduction to chromium(III) could allow a crosslinking of protein-bound 
DNA.  Redox values suggest that oxidative damage can travel to guanine-rich sites, such 
as that of the consensus sequence of κB DNA.  This suggested a mechanism by which a 
chromium oxidative event could crosslink the DNA and protein into a binary complex 
without direct chromium involvement at the site of oxidation.  Furthermore the protein, 
tightly bound to DNA, may compete with water to act as a nucleophile on DNA.  This 
binary DNA-protein complex may be covalently linked and resistant to harsh conditions, 
allowing it to be visualized by HPLC or gel electrophoretic mobility shift assays.  Under 
our conditions, no κB DNA, either unmodified or modified with 8-oxoguanine, was 
found to be bound to the p50BD protein.  DNA oxidation through chromium reduction 
was not found to result in crosslinked p50BD protein in a binary DNA—protein complex. 
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CHAPTER 1 
Introduction/Background 
 To explain what causes the initiation of cancer using a model other than the 
mutation model, pieces of the puzzle must be assembled one at a time.  For age related 
diseases, such as cancer, these model pieces include chromium as an oxidant, damaged 
DNA, and a transcription factor protein. 
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Chromium background and chromium oxidation 
 The discovery of chromium is attributed to Vaquelin in 1798, as the mineral 
PbCrO4 (crocoite) from Siberia,1, 2 but its use in stainless steel could date back through 
history to the weapons of the Hittites (conquered by Ramsey II around 1300 B.C.).3  The 
name ‘chromium’ stems from chroma (color), in reference to the wide variety of colors 
of chromium compounds.  Although the possible oxidation states range from –2 to +6, it 
commonly exists in four valence states: Cr(0), Cr(II), Cr(III), and Cr(VI).1, 4  While the 
anhydrous Cr(II) salts are relatively stable, the divalent state (II) oxidizes readily to the 
trivalent (III) state.5
O
OO- Cr
O- 
Cr
L
L L
L L
L
CrO4
2-
CrL6
+3+6
 
Figure 1.1: common chromium structures:  
Left – Hexavalent chromium; chromate.           Right – Chromium (III) 
  
 
For the human body anecdotal evidence points to the +3 oxidation state of 
chromium to be important in the interaction between insulin and insulin receptor sites, 
however this has not been scientifically established.  It has been established that excess 
chromium in the body, depending on valence states, can have unpleasant consequences 
including disease and death. 
What is of increasing concern with regard to human health is the anthropogenic 
accumulation of chromium in the environment.  Human chromium exposure is found 
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both in the workplace and in the environment.  Occupational exposures to chromium can 
be found in welding, leather and chrome plating workers as well as stainless steel and 
chrome pigment production.4
  The link between chromium and cancer was established in the late 1800s with 
the observation of nasal tumors in Scottish chrome pigment workers.  Lung cancers were 
first documented in the early 1930s in German chromate workers.1  Chromium (III) can 
cause toxic effects if these particles enter the respiratory tract and lungs and act as non-
specific irritants.6  The particles are unable to penetrate membranes which results in a low 
uptake of Cr(III) into cells. The carcinogenic form of chromium was found to be the +6 
oxidation state, with lung cancer as the most prevalent outcome from inhalation 
exposure.7, 8  Hexavalent chromium enters cells through phosphate and sulfate channels 
or by phagocytosis.  The +6 oxidation state is the second most stable state after the +3 
state,5 and it is susceptible to reduction in cellular systems.9  While Cr(VI) does not 
interact with DNA directly, there are a number of cellular reductants including 
glutathione, ascorbate, cysteine, glutathione reductase, and carbohydrates that reduce 
Cr(VI) to Cr(III).6, 10  With either a concentration gradient of higher anions outside the 
cell’s membrane or the cells need for anions such as sulfate and phosphate, the Cr(VI) 
enters through the anion channels, and is reduced to Cr(III); a concentration gradient is 
maintained and the cycle repeats.  In this method the cell can accumulate extremely high 
levels of chromium.11
Hexavalent chromium, Cr(VI), is currently listed as “carcinogenic to humans” by 
the International Agency for Research on Cancer (IARC) and the US Toxicology 
Program.12  Chromium metal and Cr(III) compounds are rated IARC 3 whereas Cr(VI) is 
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IARC 1.13  The ranking of IARC 3 is used for mixtures, agents and exposures for which 
the evidence is inadequate to classify carcinogenicity to humans but sufficient to 
conclude carcinogenicity in experimental animals.  IARC 1 indicates a known human 
carcinogen.14
The reduction of Cr(VI) to Cr(III) forms intermediate redox states of Cr(V) and 
Cr(IV).  These high-valent intermediate oxidation states of chromium are unstable and 
are capable of causing DNA damage.15  Using Cr(VI) and ascorbate creates reactive 
chromium intermediates and radicals that cause DNA damage.16  Intracellular 
accumulation of Cr(III) has been proposed to interact with DNA to yield Cr-DNA, DNA-
DNA, and DNA-protein crosslinks.15   
 While the functions of normal metabolism have been postulated to be one cause 
of age related diseases,17 chromium exposure and the metabolic by-products generated 
causing cellular damage by radicals have been postulated to be another cause of age-
related diseases.  Cellular metabolism of chromium has the possibility to create hydrogen 
peroxide (H2O2), hydroxyl radical (•OH), and superoxide (•O2-).  These oxidants are all 
capable of damaging proteins, DNA, RNA and other cell components.18  This pathway of 
free radical oxidants from metal exposure could likely be a cause of pathogenesis. 10, 19
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DNA structure, oxidation, and 7,8-dihydro-8-oxoguanine 
To investigate the second piece of the puzzle, damage to DNA, its structure and 
function must be understood.  The structure of DNA, deoxyribonucleic acid, was defined 
by Watson and Crick in 1953 as a double helix composed of ordered sequences of the 
nucleotide residues (the nucleotide bases are adenine (A), guanine (G), cytosine (C) and 
thymine (T)) linked via glycosidic bond to a five carbon sugar (2’-deoxyribose); residues 
are linked through phosphate moieties.20   
 
Figure 1.2: Double-stranded B-form (regular) DNA21
 
The function of DNA is to be the cell’s repository of genetic information.  The 
DNA is wrapped and packaged into chromosomes and protected in the cells nucleus.  
There is a basal level of DNA transcription for routine cellular needs.  Additionally, in a 
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normal functioning cell, stimulants such as radiation and viral infections elicit a cellular 
response when transcription proteins bind DNA to generate RNA which can be translated 
into protein.  The response is to fight infection or repair cellular damage. 
However, in a cell with damaged DNA, these functions and mechanisms are 
affected.  This damage to DNA includes but is not limited to DNA strand breaks and 
modifications to DNA.    Modifications to DNA were found to primarily affect the base 
guanine.  The one electron redox potential of guanine is the lowest of all the nucleobases 
at E˚ ≈ 1.29 (V vs. NHE) at pH 7.  The other bases have higher redox potentials; A ≈ 
1.42, C ≈ 1.6, T ≈ 1.7 (for the nucleoside forms, etc.).18  The more negative a number, the 
less likely it is to be reduced and more likely it is to be oxidized.  The reactivity of 
guanines toward any oxidant is also sequence specific.  When guanine is located next to a 
purine — especially another guanine — it is more reactive than if it was next to a 3’ 
pyrimidine.  Furthermore, if the sequence is increased to contain more than just two 
guanines (G), then the reactivity also increases.  Interestingly, chromium interacts 
preferentially at regions of high guanine content in double stranded DNA with GC ≈ GT 
< GA < GG < GGG < GGGG (where G is the site of damage). 22  This phenomenon is 
explained by a mechanism in which the highest occupied molecular orbital (HOMO) 
resides on the 5’G due to π-stacking in the purine runs.23  Furthermore, this site may act 
as an electron hole since oxidative damage along DNA can migrate to this location.  
Electron hole migration is known to occur in double-stranded (ds)DNA strands, where 
the electron hole can “travel” through DNA up to 300 base pairs to a site of high guanine 
content.24
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Oxidative damage to DNA is common.  Over 100 oxidatively modified bases 
have been identified in DNA,25 and these are estimated to occur at a frequency of 10,000 
per cell daily for a human cell.15, 17  This oxidative DNA damage has been separated into 
four distinct classes, 1) abasic sites, 2) strand breaks, 3) modified bases, and 4) DNA—
protein crosslinks.26  It has been suggested ~ 1 per 40,000 guanines in the human genome 
are oxidized to 7,8-dihydro-8-oxo-guanine (8-oxoguanine).26  It appears safe to assume 
that 8-oxoguanine is present constitutively in every cell.   
 
Figure 1.3A: Normal C-G base pair Figure 1.3B: C-8-oxoguanine base pair, 
with new donor/acceptor patterns 
 
8-oxoguanine is a common guanine product under oxidizing conditions, which 
includes chromium exposure.18  The normal base pairing of guanine appears, with donor 
acceptor patterns (figure 1.3A, from L R), as hydrogen bond donor, acceptor, and 
acceptor in the major groove (in Lewis acid/base form).  However, 8-oxoguanine changes 
the major groove donor/acceptor pattern and adds an additional acceptor bond (figure 
1.3B).  The specific effect of the oxidation on guanine at C8 is that the N7 transforms 
 8
from H-bond acceptor to donor, and the C8 becomes a strong H-bond acceptor at the 
oxygen (circled in red).  The minor groove, as marked above, does not change in 
donor/acceptor patterns.  
8-oxoguanine in the sequence 5’-CCA GoCG CTGG-3’, where Go represents 8-
oxo modification, was crystallized in 1995 by Lipscomb, et al. (183D.pdb).27  The 
divergence in structure between a regular guanine versus 8-oxoguanine is very slight in 
an oligomer.  The only change discerned when 8-oxoG containing DNA was overlaid 
with the same sequence DNA was in residue 4 (Go) seen in the torsion angle χ from O4’-
C1’-N9-C4 (the glycosidic bond region) for the guanine residue location of interest. 
 
8-oxoG 
Figure 1.4: 8-oxoguanine-containing double-stranded B-form DNA21
183D.pdb,27 the 8-oxo moiety tucked behind the sugar is accessible in the major groove. 
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Further oxidized lesions 
The oxidative product of guanine, 8-oxoguanine, is prone to further oxidation.28  
Studies on the one electron redox potential for 8-oxoguanine nucleoside suggest E˚ ≈ 
0.58 V vs. NHE at pH 8, less than that of guanine at pH 7, where E˚ ≈ 1.29.18  The factors 
influencing the location-dependent guanine oxidation (5’-GGGG-3’) will also influence 
8-oxoguanine further oxidation.   
With water as the nucleophile attacking at the C5 position on 8-oxoguanine, 
recent studies have indicated that guanidinohydantoin (Gh) and spiroiminodihydantoin 
(Sp) are the major products of 8-oxoguanine oxidation (by chromium(VI)).29  The 
chemical structures of these further oxidized lesions are shown below, with the C5 
locations indicated by arrows: 
 
N
N
N NH2
O
O
NH
H
HDNA
HN
N N
NH
NH
OO
O
DNA H
Gh Sp
 
Figure 1.5: Nucleophilic attack by water at C5 of 8-oxoguanine produce Gh and Sp 
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Transcription factor protein chemistry 
To understand DNA—protein binding and the altered protein binding affinities 
with damaged DNA, transcription factor protein (TFP) biochemistry must be understood.  
DNA—transcription factor protein interactions drive the sequence-specific nature of TFP 
binding.  TFPs can be split into two distinct categories, the general and the sequence 
specific.30  General TFPs employ cellular machinery, including RNA polymerase, that 
bind based on the promoter ‘start’ sequence of the TATA box AT-rich region.  Unlike the 
general TFPs, specific TFPs bind to particular motifs in the sequence of the promoter 
region of the gene and then utilize the general TFP machinery. 
 Upon binding, the protein’s amino acids make specific hydrogen and electrostatic 
bonding interactions.  Examples are histidine with a positively charged (acidic) residue 
containing an imidazole ring, and lysine, protonated under physiological conditions.  
Both amino acid residues are involved in hydrogen bond interactions.  
+H3N C
H
COO-
CH2
HN1 N3
C5
HN1
C2
N3
C4
Imidazole
Histidine
+H3N C
H
COO-
CH2
CH2
CH2
CH2
NH3
+
Lysine
 
Figure 1.6: Charged structures with potential to crosslink DNA 
 
Many TFPs have been well characterized, specifically AP-1, p53, and NF-κB 
which are classified as (oncogenic) activating protein, tumor suppressor protein, and 
signal transducer protein respectively.30, , 31 32  The balance of activation or inactivation of 
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regulation is complex; either action in excess ostensibly leads to tumorigenesis.  
Mutations in transcription factor proteins, depending on the location, have the potential to 
produce severe cellular consequences, eventually resulting in disease or death.  However, 
the exact genetic causes of disease cannot always be neatly explained by a conventional 
mutation model.  What is known for certain is that when control is lost over gene 
expression, specifically the DNA—protein binding, the impact is seen in the gene 
product.   
It has emerged that several tightly controlled regulatory DNA elements of a cell, 
such as the genes for NF-κB and p53, contain a consecutive run of guanines in their 
promoter sites and that these areas are redox sensitive.33, 34  Many of these promoters 
drive genes that are transcribed during an oxidative attack on DNA.  Conserved guanine 
sequences within promoter sites can be considered an evolutionary design to modulate 
gene expression during an oxidative event rather than an evolutionary ‘flaw’.  Logic 
dictates that there is a reason that DNA has evolved to have these oxidation-prone run of 
guanine regulatory elements.  It is possible that the oxidized sequences recruit proteins 
based on of the type of the modification, in a similar mode to non-modified sequences 
which recruit transcription factor proteins based on cellular needs. 
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Covalent crosslinking   
DNA-protein binding has been investigated for many decades.  Mammalian 
DNA-protein crosslink existence was established in the late 1980s.35  Much is known 
about chromium reactions within a cell;6 it is established that Cr(VI) is carcinogenic and 
that a reduced form of chromium(VI) creates DNA-protein crosslinks, but the mechanism 
of how crosslinks are formed remains a mystery.  Determining the exact role of 
chromium, Mattagajasingh and Misra suggested that, “…the nature of chromate-induced 
DNA-protein crosslinks is not fully resolved.”36  Currently chromium is thought to form 
ternary adducts with DNA in cellular systems. 6, 36, 37,  38  In this conventional model only 
Cr(III) is directly involved in the crosslink and both DNA and proteins are thought to be 
ligands of the chromium metal complex.37
  The theory of Mattagajasingh and Misra was that intracellular reduction of 
Cr(VI) to Cr(III) creates species such as chromium(V) and chromium(IV), and reactive 
oxygen species.  These species mediate the crosslinks directly in ternary structures: 
DNA-Cr-protein, where the DNA and the protein are metal ligands.  Recent papers 
further propose that reduced forms of chromium are unstable crosslinks; that Cr(V) and 
Cr(IV) will not be found in stable ternary covalent crosslinks.38  Yet many factors at the 
DNA-protein interface could allow a chromium oxidative event to crosslink the DNA and 
protein without direct chromium involvement.  Therefore, in the reduction of the forms of 
Cr(V) or Cr(IV) to Cr(III), the DNA could be oxidized at the protein hydrogen-bound 8-
oxoguanine DNA thereby covalently crosslinking the DNA—protein in a binary 
complex, rather than a ternary complex.  
 13
Many pieces of the puzzle come together to form a theory supporting a binary 
covalent crosslink of DNA and protein.  First, it has been seen that modified DNA can 
recruit and hydrogen bond protein.  When protein is bound to modified DNA it 
potentially excludes the water – the nucleophile required to generate Gh or Sp under 
further oxidizing conditions.   Next, chromium can interact preferentially at these gene 
promoter regions of DNA with high guanine content, based on the redox potentials of 
both the chromium and the guanine-rich area, and further oxidize the DNA.  
Consequently, when chromium performs an oxidative event on the modified DNA, the 
protein can act as a nucleophile, and the oxidation could potentially crosslink the DNA—
protein together in a binary complex. The theory that this binary complex is created from 
covalent crosslinking of modified DNA to protein by chromium oxidation incorporates 
two of the classes of oxidative DNA damage (the modified base and the DNA—protein 
crosslink).  This binary covalent linkage may also block transcription by shielding the 
modified base from repair which would have a long-term impact on global gene 
expression.  The binary covalent link would explain the initial causes of disease states 
beyond that of the simplified mutation model.  Furthermore, this method of DNA—
protein crosslinking explains a role of chromium in oxidative events. 
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Investigations into DNA—protein  crosslinking 
The investigations performed to elucidate the exact mechanism of crosslinks have 
involved an NF-κB DNA oligonucleotide, lab-generated protein, and several species of 
chromium.  The dsDNA oligonucleotide has a run of four guanines; the non-modified 
(control) strand is utilized along with versions of a single modified guanine in each of the 
four sites. 
The first step in elucidating crosslinks was to determine the electrostatic and 
hydrogen bond interactions of the protein with each of the dsDNA strands.  Once 
established, the chromium species could be added to determine the effect of chromium 
oxidation on non-modified DNA—protein as well as modified DNA—protein binding.  
To determine that bonding was covalent rather than electrostatic, a denaturing 
environment was used to select for covalent bond resistance to degradation. 
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CHAPTER 2 
p50 Protein background and interactions: 
History of NF-κB: 
Nuclear factor of the κ-light chain of B cells (NF-κB) controls gene expression 
through recognition of κB sequences in the promoter regions of DNA.1  The NF-κB 
family of proteins are transcription factor proteins that regulate a wide range of responses 
to infection and inflammation.  The proteins mediate cell proliferation, cell 
transformation, angiogenesis, cell invasion, cell immunity, apoptosis, and hematopoiesis.2  
NF-κB is part of a larger family of Rel proteins, containing Rel homology domains that 
bind DNA as hetero- or homodimers in the nucleus.3  The active dimer exists in an 
inactive state as a heterotrimer in the cytoplasm where the dimer is bound with an IκB 
inhibitor protein (IκB-α, IκB-β, IκB-γ, Bcl-3, and cactus).  Activation causes 
phosphorylation and ubiquitination of the inhibitory protein and the free NF-κB dimer 
then translocates into the nucleus.  The five members of the NF-κB are p65 (RelA), RelB, 
c-Rel, p50 (NF-κB1) and p52 (NF-κB2).  The most common NF-κB protein is the 
p50/p65 heterodimer.4
The proteins bind DNA sequences, called κB DNA enhancer elements.  The 
generic κB DNA consensus site, which will bind all NF-κB proteins, has been determined 
to be a ten base pair sequence, 5’-GGG RNW YYC C-3’ (where N is any nucleotide, Y is 
pyrimidine, R is purine, and W is A or T).5  Hundreds of variations of this κB DNA 
sequence exist in gene promoters.5  Most dimers can associate with varying binding 
affinities to different κB DNA sites.  These small differences in binding affinities for κB 
sequences can have an impact on the expression of genes, implying that the role of the 
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DNA sequence and its conformation has an important responsibility in gene expression 
with the NF-κB protein.5  Huang et al. proposed to organize the κB sites into two distinct 
classes, class I for p50 and p52 hetero- and homodimer binders, and class II for p65 and c-
Rel hetero- and homodimers.5   
The ten base pair consensus sequence contains the class I κB site of 5’-GGG RN-
3’ half-site and the class II κB site of 5’-YYCC-3’ half-site.  The most 5’-G for class I κB 
is in contact with a histidine side chain that is exclusive to p50 and p52 which gives rise 
to sequence specificity.  For p65 and c-Rel, the histidine in the protein sequence is 
replaced with an alanine.  The impact for these sequence specificities is that the 
homodimers of p50 and p52 bind optimally to 11 base pair κB sites, heterodimers with 
p50 or p52 prefer 10 base pair sites, and homodimers of p65 or c-Rel prefer 9 base pair 
κB sites.5
Ghosh et al.6 and Müller et al.7 crystallized residues 39-364 for the mouse p50 
protein and residues 2-366 for the human p50 protein, respectively.   For Ghosh et al., 
these truncated protein constructs bound both the κB sequence and I-κB.  For Müller et al. 
the truncated protein was the most stable fragment that was proteolytically cleaved from 
p105 to create p50 ending at the nuclear localization signal (Figure 2.1). 
The Rel homology domain folds into two subunits, the larger N-terminal domain 
which contacts DNA base pairs and the smaller C-terminal domain which is responsible 
for dimer formation and DNA phosphate contact.  Residue proline 43 marks the 
beginning of the Rel homology domain; residues 160-205 form an α-helical like structure 
within the Rel domain but are not part of the domain.  Residues 250 – 366 mark the C-
terminal domain and residue 366 marks the end of the nuclear localization signal.  
 22
Residues 244-250 form a flexible linker region between the two domains which is not 
stabilized by H-bonds or hydrophobic contacts which makes it ideal as a flexible hinge for 
the protein to bind to or dissociate from DNA. 
 
 
Figure 2.1: Structure of p105/p50 Adapted from Gilmore, et al. (1996) Oncogene 13, 
1367-1378. 8   RHD – Rel Homology Domain; PK – protein kinase A recognition 
sequence; NTS – nuclear targeting sequence also known as nuclear localization signal. 
Protease cleaves as indicated to form p50 from p105, leaving the N-terminus intact. 
 
 
DNA recognition 
 Both the N- and the C-terminus contact DNA.  The protein binds in the major 
groove and in the p50 homodimer, at the dimer interface, the C-terminus domains wrap 
around the DNA for phosphate interactions.  The N-terminal domain covers the 5’-
GGGGAC-3’ half site.  The C-terminal domain is composed of six variable loops.  The 
N-terminal domain contains nine variable loops, two of which comprise the κB DNA 
recognition loops, allowing for flexibility in protein conformation and binding DNA.  The 
N-terminal domain does not contribute to the protein dimerization interface.   Specific 
DNA recognition by p50 is shown in Figure 2.2, page 23.  When p50 binds DNA, there a 
slight deviation from B-form DNA with the unwinding and a slight bend of DNA.  There 
is no extreme distortion of DNA by the protein.6
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Figure 2.2: p50 protein binding κB DNA consensus sequence 5’-GGGGACTTTCCCC-
3’ / 5’-GGGGAAAGTCCCC-3’, adapted from Ghosh, G., et al. Nature 373, 303-310, and 
Müller, C.W., et al (1996) Nature 373, 311-317. 6, 7
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Site-specific changes to p50BD to create a mutant protein 
We have previously shown that a 22-mer double-stranded DNA sequence (5’-
AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’) with an 8-oxoguanine in each of the 
numbered guanines sites gave discrete p50 protein binding affinities depending upon the 
location of the 8-oxoguanine lesion.9  The histidine in position 67 of the human p50 
protein is important in DNA binding as the histidine would contact the 8-oxoguanine at 
position G1.  The C5 of 8-oxoguanine, a vinyl carbon, could be subject to nucleophilic 
attack by either of the histidine’s nitrogens at position 67 during an oxidative event (see 
Figure 2.3).  As an 8-oxoguanine in specific NF-κB sequence positions could impact 
binding affinities, a mutant was engineered with the histidine changed to an alanine in 
order to mimic p65 or c-Rel binding.   In addition, the engineered p50 protein consisted of 
only the DNA binding domain, residues 23-366. 
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Figure 2.3: Mechanism of nucleophilic attack. 
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Table 2.1:  DNA and protein sequence comparisons of the p50 binding domain protein 
and p50 mutant protein 
Comparison of protein sequences 
p50BD GAA GGC CCA TCC CAT GGT GGA CCT GGT 
Translation of 
p50BD (1 letter 
protein code) 
H T I F N P E V F Q P Q M A L P T D G P Y L Q I L E Q P K 
Q R G F R F R Y V C E G P S H G G L P G A S S E K N K K 
S Y P Q V K I C N Y V G P A K V I V Q L V T N G K N I H 
L H A H S L V G K H C E D G I C T V T A G P K D M V V 
G F A N L G I L H V T K K K V F E T L E A R M T E A C I 
R G Y N P G L L V H P D L A Y L Q A E G G G D R Q L G 
D R E K E L I R Q A A L Q Q T K E M D L S V V R L M F T 
A F L P D S T G S F T R R L E P V V S D A I Y D S K A P N 
A S N L K I V R M D R T A G C V T G G E E I Y L L C D K 
V Q K D D I Q I R F Y E E E E N G G V W E G F G D F S P 
T D V H R Q F A I V F K T P K Y K D I N I T K P A S V F V 
Q L R R K S D L E T S E P K P F L Y Y P E I K D K E E V Q 
R K R Q K L Stop Stop 
 
P50H67A GAA GGC CCA TCC GCA GGT GGA CCT GGT 
Translation of 
p50H67A (1 
letter protein 
code) 
H T I F N P E V F Q P Q M A L P T D G P Y L Q I L E Q P K 
Q R G F R F R Y V C E G P S A G G L P G A S S E K N K K 
S Y P Q V K I C N Y V G P A K V I V Q L V T N G K N I H 
L H A H S L V G K H C E D G I C T V T A G P K D M V V 
G F A N L G I L H V T K K K V F E T L E A R M T E A C I 
R G Y N P G L L V H P D L A Y L Q A E G G G D R Q L G 
D R E K E L I R Q A A L Q Q T K E M D L S V V R L M F T 
A F L P D S T G S F T R R L E P V V S D A I Y D S K A P N 
A S N L K I V R M D R T A G C V T G G E E I Y L L C D K 
V Q K D D I Q I R F Y E E E E N G G V W E G F G D F S P 
T D V H R Q F A I V F K T P K Y K D I N I T K P A S V F V 
Q L R R K S D L E T S E P K P F L Y Y P E I K D K E E V Q 
R K R Q K L Stop Stop 
 
 The binding affinities for the p50 binding domain protein with the five 
oligonucleotide sequences, four of which contain 8-oxoguanine modifications, were 
investigated.  For the p50H67A mutant with the control and the 8-oxoguanine DNA 
modified at position G1, the binding affinities were investigated.  An apparent binding 
constant, Kapp, was determined for each protein-DNA modification as the point where the 
fraction bound equals 50% graphically. 
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Materials and methods: 
Deoxyribonucleotides.  Unmodified oligonucleotides with the κB consensus sequence 
were obtained from IDT DNA (Coralville, IA).  Modified 22-mer DNA sequences 
containing an 8-oxoguanine in the NF-κB protein p50 homodimer consensus sequence 
(5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’, where the bold bases indicate the 
consensus sequence and the G1-4 indicate positions of 8-oxoguanines in the recognition 
sequence) were obtained from TriLink Biotechnologies (San Diego, CA).  Modified 30-
mer DNA sequences containing the sequence 5’- TCC GCT G1G2G3 G4AC TTT CCG 
CGG AGA CTC TAG -3’ (again the bold bases indicate the consensus sequence and the 
G1-4 indicates positions of 8-oxoguanines in the recognition sequence) were also obtained 
from TriLink Biotechnologies.  HPLC purification of the 22-mer oligonucleotide strands 
was performed using a Dionex DNAPac PA-100, 4 mm x 250 mm anion exchange 
column.  Elution was accomplished with a linear gradient of 90% mobile phase A (10% 
aqueous acetonitrile) and 10% mobile phase B (1.5 M ammonium acetate (pH 6.2), 10% 
acetonitrile) to 100% mobile phase B over the course of 22 minutes.  The 30-mer 
oligonucleotide was purified in a similar manner, however mobile phase A also contained 
500 mM NaCl and elution was accomplished with a linear gradient of 90% A and 10% B 
to 100% mobile phase B over 30 minutes.  Column elutions of oligonucleotides were 
observed by diode array at 268 nm.  The single-peak elution of oligomer was evaporated 
to remove the volatile acetonitrile, eluted through a BioRad chromatography column 6 
and stored at -20˚C until needed for testing.  The NaCl from the 30-mer oligonucleotides 
was removed by elution through a BioRad chromatography column 30.  Standard methods 
were employed to 5’- 32P end-label specific oligomers.  The control or 8-oxoguanine 
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containing single stranded DNA was incubated with polynucleotide kinase and 10 µCi of 
32P-γ-ATP for 30 minutes.  Column elutions with a Micro Bio-Spin 6 chromatography 
column from BioRad (Hercules, CA) removed the enzyme and unincorporated 
nucleotides.  The radiolabeled single stranded DNA was annealed to complement DNA 
by heating to 95˚C and slowly cooling 1˚C / 1 minute using a Peltier Thermal Cycler from 
MJ Research (BioRad, Waltham, MA). 
NF-κB p50BD Transcription Factor Protein.  The p50 binding domain sequence from 
residues 23 to 366 was created using an I.M.A.G.E. clone of the p105 protein as a PCR 
template.  The p50 binding domain region was amplified by PCR using primers from IDT 
DNA.  The p50BD DNA contained engineered restriction sites EcoR I and Xba I at the 5’- 
and -3’ ends respectively.  These primers were p50EcoR1H23For (5’-GGA ATT CCA 
TAC AAT AAT TAA TCC AGA A-3’) and p50Rev (5’-AGG CTC TAG ATT TCA TCA 
GAG CTT CTG ACG TTT CCT-3’).  The pPROEX HTa plasmid (Invitrogen) was 
transformed into competent GW1678, a dam- and dcm- E. coli strain (E. coli Genetic 
Stock Center).  The E. coli were made competent by picking colonies from freshly 
streaked plates and growing overnight at 37˚C in LB media; 2 mL of the overnight culture 
was then grown in 100 mL of LB-media at 37˚C until OD260 was 0.3 to 0.4.  The culture 
was collected in 50 mL tubes and centrifuged at 4000 rpm for 15 minutes at 4˚C, and then 
the liquid was drained.  The pellet was re-suspended in approximately 16.5 mL solution A 
(100 mM RbCl, 50 mM MnCl2·H2O, 30 mM KCH3COOH, 10 mM CaCl2·2H2O, 15% 
(v/v) glycerol, pH 5.8 by 0.2 M CH3COOH, and filter sterilized), incubated on ice for 30 
minutes and centrifuged at 4000 rpm for 15 minutes at 4˚C.  The pellet was re-suspended 
in approximately 4 mL solution B (10 mM MOPS, 10 mM RbCl, 75 mM CaCl2·2H2O, 
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15% (v/v) glycerol, pH 6.8 with NaOH and filter sterilized) and incubated on ice for 15 
minutes.  Aliquots were distributed into microcentrifuge tubes, flash frozen in dry 
ice/ethanol mixture and stored at -80˚C.10  The plasmids were amplified in this strain to 
provide a non-methylated plasmid as subsequent restriction enzymes are inactive on 
methylated DNA.  The PCR insert and plasmid were cut with  EcoR I and Xba I, ligated 
with Quick Ligase (New England Biolabs, Ipswich, MA) at room temperature for five 
minutes, chilled on ice, and then transformed into XL-10 Gold Ultracompetent cells 
(Stratagene, La Jolla, CA).  The transformations were performed by mixing gently 100 µL 
of competent cells in ice-cold 14 ml BD Falcon polypropylene round-bottom tubes with 
1.7 µL β-mercaptoethanol (1.42 M) over 10 minutes.  The ligation mixture was added to 
the tubes (130 ng, ~3 µL) and the mixture was incubated on ice for 30 minutes.  The cells 
were heat-pulsed for 45 seconds at 42˚C, and chilled on ice for 2 minutes.  NZY+ media 
(900 µL, 42˚C, NZY+: 10 g NZ amine, 5 g yeast extract, 5 g NaCl, deionized H2O to 1 L, 
pH 7.5, autoclave.  Prior to use a 12.5 mL filter sterilized solution of 1M MgCl2, 12.5 mL 
1M MgSO4, and 20 mL 20% (w/v) glucose was added and the cells were incubated at 
37˚C for 1 hour with 225 rpm shaking.  Approximately 200 µL competent transformed 
cells were spread on fresh LB-ampicillin 3% agar LB plates and incubated overnight at 
37˚C.   Insert verification by PCR was performed before sequencing using the procedure 
that follows.  Ten clones that grew on the ‘plasmid + insert’ plate were isolated using a 
QIAprep kit (Qiagen, Valencia, CA).  The plasmid DNA, containing insert was grown 
overnight in 15 mL tubes at 37˚C in LB media after picking colonies from the ‘plasmid + 
insert’ plates.  The culture was centrifuged at 4000 rpm for 15 minutes at 4˚C, the liquid 
was drained, and the pellet was frozen at -20ºC.  The plasmid DNA was isolated using a 
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Qiagen miniprep kit according to manufacturer’s directions.  The plasmid DNA 
concentrations for the ten clone samples were determined by measuring OD260/280; 10 ng 
aliquots from each of the ten plasmid samples were PCR incubated with the forward and 
reverse cloning primers described earlier and then run on a 1.2% agarose gel.  Two 
successful clones showing the insert were selected for sequencing to verify the presence 
of insert and to ensure the clone was error free and then transformed into BL21 (DE3) 
expression cells (Stratagene).  Sequencing primers used were the p50EcoR1H23For, 
p50Rev, p50seqfor (5’-GAC AAA GTT CAG AAA-3’) and p50seqrev (5’-GAT CCC 
ATC CTC ACA-3’).  The cell transformation into the BL21 (DE3) E. coli was similar to 
the procedure for the XL-10 Gold Ultracompetent cells except the media used was room 
temperature SOC (20g tryptone, 5 g yeast extract, 0.5 g NaCl, deionized H2O to 1 L, 
autoclave; added prior to use, filter sterilized 10 mL of 1M MgCl2, 10 mL 1M MgSO4, 2 
mL 20% (w/v) glucose).  
Protein mutations.  A Quikchange® site-directed mutagenesis kit (Stratagene) was used 
to create the histidine to alanine mutation.  This kit allows for site-directed mutagenesis in 
double-stranded miniprep plasmid DNA.  The p50BD (binding domain) plasmid DNA 
was incubated with complementary oligonucleotide primers containing the mutation 
sequence.  The forward primer H64Afor (5’-TAT GTG AAG GCC CAT CCG CAG GTG 
GAC TAC CTG GTG-3’) and reverse primer H64Arev (5’-CAC CAG GTA GTC CAC 
CTG CGG ATG GGC CTT CAC ATA -3’) were extended with PfuTurbo DNA 
polymerase during temperature cycling.  The primers created new, mutated plasmids 
having nicks/non-overlapping single strand breaks that were capable of transformation 
into competent cells.  The products were Dpn I endonuclease treated to remove 
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methylated and hemimethylated DNA (only the parental plasmid DNA is methylated).  
This enzyme targets 5’-GmATC-3’ sequences.  The final step was the vector DNA 
transformation into XL1-Blue supercompetent cells.  Fresh LB-ampicillin 3% agar plates 
with IPTG (isopropylthio-β-D-galactoside) and X-gal (5-bromo-4-chloro-3-inodlyl-β-D-
galactopyranoside) were prepared; the plates were incubated at 37˚C for greater than 16 
hours to allow for blue colonies to evolve indicating a successful transformation.  Plasmid 
DNA for p50H67A was isolated as described earlier and PCR incubated with the 
p50EcoR1H23For and p50Rev primers and run on a 1.2% agarose gel.  One successful 
clone showing the insert was selected for sequencing to verify insert and transformed into 
BL21 (DE3) protein expression cells (Stratagene).   
Protein purification.  The expression plasmids, in BL21 (DE3) cells, were grown to an 
OD600 of 0.3-0.6 at 37˚C in LB media containing 25 µg/mL ampicillin, as the pPROEX 
HTa contains an ampicillin resistance cassette.  Cells were induced with IPTG to a final 
concentration of 0.1 mM and incubated for 4 hours at 37˚C.  Cells were then harvested by 
centrifugation at 4˚C and 5,000 rcf, and frozen at -20˚C for later use.  After thawing on 
ice, cells were lysed using the BugBuster® protocol and reagent (Novagen, 5 mL reagent 
per gram wet cell paste), lysozyme (Sigma, 0.5 mg per gram wet cell paste), Benzonase 
nuclease (Novagen, 1 µL per mL BugBuster® reagent), and protease inhibitor cocktail 
(Roche, 1 tablet dissolved in 2 mL H2O, use 0.2 mL per 5 mL extraction reagent).  Cell 
lysate was filtered through a Ni-NTA column (Qiagen).  Protein was washed with 
Solution A and B (50 mM NaH2PO4, 300 mM NaCl, with 10 mM and 20 mM imidazole 
respectively) and eluted with Solution C (50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazole).  The elution fraction was de-salted using a Microcon YM-10 and eluted into 
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protein storage buffer (20 mM HEPES, 50 mM NaCl, pH 7).  An aliquot was reserved for 
BCA protein concentration analysis (BCA kit, Pierce, Rockford, IL), and the remaining 
sample was diluted in half with protein storage buffer containing 40% glycerol, aliquoted 
into 15-25 µL sub-samples depending on protein concentration, and stored at -80˚C. 
 Electromobility Shift Assay (EMSA or gelshift).  DNA-protein binding reactions were 
performed using 2.6 µM 5’-32P radioactive-labeled DNA which had been annealed to its 
complement to create double stranded DNA (dsDNA).  The reaction buffer for the DNA-
protein binding was acquired from Promega [buffer: 20% glycerol, 5 mM MgCl2, 2.5 mM 
EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCL, pH 7.5, 0.25 mg/mL poly(dI-
dC)].  The DNA and protein were allowed to react for 20 minutes before running on a 
polyacrylamide gel; either a native 4% polyacrylamide gel or a 6% Invitrogen pre-poured 
retardation gel.  Additionally, glycerol (1 µL, 40%) was added to all reaction mixes to 
increase density and help with sample loading.  Unless a free well was available for dye 
only, the sample ‘DNA only’ was the only well to have loading dye added in order to 
minimize any interference of the dye with the DNA and protein binding interactions.  The 
gels were run at 250-300 V for ~10 minutes.  The gel shifts were analyzed by 
autoradiography (Kodak). 
Data Analysis. The EMSA analysis of binding affinity for the control and the 8-
oxoguanine modified oligonucleotides was performed using GS 800 Calibrated 
Densitometer from BioRad, by integrating the area for each band and dividing the area of 
the protein-bound DNA by the total area of the free and bound DNA bands to yield a 
percent bound.  The software used was PDQuest 2-D gel analysis software to scan the gel 
image and Quantity 1 analysis software to determine the physical area to integrate.  The 
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apparent dissociation constant Kapp was determined as the point where the fraction bound 
equals 50% graphically. 
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Results:  
Cloning and mutagenesis of the p50 DNA binding domain 
The p50BD PCR product ligated into pPROEX HTa was transformed into XL-10 
Gold Ultracompetent cells as these cells are engineered for superior uptake efficiency of 
plasmid DNA.  For protein expression the plasmid was transformed into BL21 (DE3) 
cells.  The presence of the insert was confirmed by PCR using the original cloning 
primers to amplify an ~1000 base pair fragment from the isolated plasmid (see arrow 
pointing to 1000 base pair molecular marker, Figure 2.4).  Six of the first ten clones (5-10, 
Figure 2.5) contained insert and four did not (1, 3, 4, and 11).  The lane marked ‘0’ is a 
template-free PCR control lane. 
 
1000 
1500 
500 
Figure 2.4: PCR of p50BD clone, arrow at molecular marker 1000 base pairs. 
 
 
For the mutant of p50BD, p50H67A, to confirm the presence of insert, PCR was 
performed using the original p50BD cloning primers.  Figure 2.5 indicates that all the 
clones loaded onto the gels contained insert of the correct size ~ 1000 base pairs (see 
arrow at 1000 base pair molecular marker).  All seven clones selected (1-7, Figure 2.5) 
contained insert.  The lane marked ‘0’ is a template-free PCR control lane. 
 34
 
 1500 
1000 
500 
Figure 2.5: PCR of p50H67A, arrow at molecular marker 1000 base pairs. 
 
The Chromas sequencing determined that the clone p50BD DNA was error free.  
The mutation DNA, p50H67A, was also found to be in agreement with the expected 
sequence and error free (see Table 2.1, page 25, and Figure 2.6). 
 
A 
B 
Figure 2.6: Sequence of proteins at mutation site 
A: (top) sequencing of p50BD    
B: (bottom) sequencing of p50H67A (area circled in red, 3 base mutations underlined). 
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Expression of the wild type and mutant p50BD protein 
 Transformed BL21(DE3) cells containing p50BD or p50H67A plasmids were 
grown to OD600 of 0.3-0.6, induced with IPTG, and incubated for 4 hours at 37˚C.  The 
proteins were purified with a Ni-NTA column as described in Materials and Methods.  
The proteins were washed with Solution A and an aliquot was collected (W1 in Figure 2.7 
for p50BD).  The second wash, W2, of the column-bound protein with Solution B 
removed trace protein impurities (see W2, Figure 2.7).  The protein elution was 
performed using two volumes of Solution C and aliquots show a band at the correct 
molecular weight for p50BD, 42,400 Da (band at E1 and E2, Figure 2.7).  The elution 
fraction E1 was de-salted using a Microcon YM-10, eluted into protein storage buffer, and 
stored at -80˚C. 
 
Figure 2.7: p50BD protein purification.  Protein elution by imidazole at E1 and E2. 
 
 The elution of p50H67A was performed using two volumes of Solution C and 
aliquots show the molecular weight of p50H67A, 42,400 Da (band at E1 and E2, Figure 
2.8).  The elution fraction was de-salted using a Microcon YM-10, eluted into protein 
storage buffer, and stored at -80˚C. 
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Figure 2.8:  p50H67A protein purification.  Purified p50H67A protein elution at E1, with 
some elution at W2 and E2. 
 
DNA-protein interactions.   
To investigate DNA-protein binding, oligonucleotides were ordered from IDT DNA and 
TriLink DNA.  The “control” sequences for the 22-mer and 30-mer oligonucleotide 
strands represents unmodified DNA and provides a basis for determining the ratio of 
DNA to protein for a gel shift.  The 30-mer oligonucleotide sequences were used for 
binding comparisons of mutant protein to wild type binding domain protein.  An 8-
oxoguanine modification was made at every guanine indicated by O.  In this manner, each 
guanine in the consensus sequence had its modification evaluated by binding affinity. 
 
Table 2.2: Sequence of 22-mer and 30-mer DNA; bold at the consensus site.  Table 
adapted from Hailer-Morrison, et al (2003) Biochem. 42, 9761-9770. 9
Oligomer strands, O indicates 8-oxoguanine position 
22-mer control 5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’ 
22-mer modified 5’-AGT TGA G1OG2G3 G4AC TTT CCC AGC C-3’ 
5’-AGT TGA G1G2OG3 G4AC TTT CCC AGC C-3’ 
5’-AGT TGA G1G2G3O G4AC TTT CCC AGC C-3’ 
5’-AGT TGA G1G2G3 G4OAC TTT CCC AGC C-3’ 
30-mer control 5’-AGT TGA G1G2G3 G4AC TTT CCC AGA CTC TAG-3’ 
30-mer modified 5’-TCC GCT G1OG2G3 G4AC TTT CCG AGA CTC TAG-3’ 
5’-TCC GCT G1G2OG3 G4AC TTT CCG AGA CTC TAG-3’ 
5’-TCC GCT G1G2G3O G4AC TTT CCG AGA CTC TAG-3’ 
5’-TCC GCT G1G2G3 G4OAC TTT CCG AGA CTC TAG-3’ 
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Interaction of the 22-mer κB-DNA oligomer control sequence with p50BD: 
     
B 
A  
Figure 2.9: 22-control κB DNA with p50BD. 
Lanes 1-8: dsDNA + p50BD (0, 0.457, 0.914, 1.37, 1.83, 2.29, 2.74, and 3.20 µM protein) 
 
 
Electrophoretic mobility shift assays show DNA binding to protein visualized by 
autoradiography.  The bound DNA-protein (arrow B in figure 2.9) is of higher molecular 
weight due to electrostatic/hydrogen bond interactions and this entity moves more slowly 
through a gel than free oligomer (arrow A in figure 2.9).  Figure 2.9 also shows that the 
protein is active and binds to the κB DNA sequence.  An approximately 50% shift of the 
DNA is accomplished using 0.457 µM p50BD protein (lane 2 as compared to zero shift 
from lane 1, no protein) and a complete shift with 0.914 µM protein (lane 3).  Excess 
protein confirms the 100% shift of 0.914 µM p50BD (lanes 4 – 8, Figure 2.9). 
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Interaction of the 22-mer κB modified at G1 DNA sequence with p50BD: 
   
B  
A  
Figure 2.10: 22G1 κB DNA with p50BD. 
Lanes 1-10: dsDNA + p50BD (0, 0.471, 0.942, 1.414, 1.885, 2.356, 2.827, 3.298, 3.769, 
and 4.241 µM protein). 
 
The 8-oxoguanine modification at G1 for the 22 base pair oligomer (Figure 2.10) 
shows that the protein does not bind as well to the modified strand as it does for the 
control.  In fact, the same amount of protein that would 100% shift unmodified κB DNA 
sequence – lane 3, ~ 1 µM, figure 2.9 – will only shift the 22-mer with an 8-oxoguanine at 
position G1 by approximately 25%.  A complete shift is not seen until lane 9, with 3.769 
µM of protein, which is four times as much protein as unmodified DNA requires. 
 
Interaction of the 22-mer κB modified at G2 DNA sequence with p50BD: 
Two distinct bands were observed (Figure 2.11) when p50BD protein is incubated 
with a 22-mer κB sequence modified in the G2 position with an 8-oxoguanine.  These 
results indicate that the monomer can bind the maximum amount of 100% of the DNA 
(arrow B).  At high protein concentrations a putative p50BD dimer is at a still higher 
molecular weight (DNA-p50BD2) and this second band appears (Figure 2.11, arrow C).  
As the amount of protein is increased, the putative dimer begins to bind the 22G2 κB 
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DNA and the amount of DNA bound by the monomer begins to decrease (Figure 2.11, 
lanes 6-9, see arrows B and C).     
 
 
1 2 3 4 5 6 7 8 9
  bottom of 
  wells 
B  
C  
A  
Figure 2.11: 22G2 κB DNA with p50BD. 
Lanes 1-9: dsDNA + p50BD (0, 0.471, 0.942, 1.414, 1.885, 2.356, 2.827, 3.298, and 
3.769 µM protein). 
 
 
Interaction of the 22-mer κB modified at G3 DNA sequence with p50BD: 
Only one faint binding band is observed (Figure 2.12) when p50BD protein is 
incubated with a 22-mer κB sequence modified in the G3 position with an 8-oxoguanine.  
These results indicate that the p50BD can only bind a limited amount of κB DNA with an 
8-oxoguanine in the G3 position (Figure 2.12, see arrow B).  A large residual amount of 
unbound DNA remains (lanes 4-9, arrow A). 
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1 2 3 4 5 6 7 8 9
bottom of
B  
A  
Figure 2.12: 22G3 with p50BD.  
Lanes 1-9: dsDNA + p50BD (0, 0.471, 0.942, 1.414, 1.885, 2.356, 2.827, 3.298, and 
3.769 µM protein) 
 
 
Interaction of the 22-mer κB modified at G4 DNA sequence with p50BD: 
8-oxoguanine modified at position G4 binds p50BD protein in a similar manner to 
the above gels with p50BD and κB DNA (Figure 2.9-2.12); unlike the 22-mer G2 (Figure 
2.11), there is only one binding band is clearly observed (Figure 2.13), but it is possible 
that an unresolved second band for the dimer exists in lanes 7-10.  These results indicate 
that the p50BD binds κB DNA with an 8-oxoguanine in the G4 position with an affinity 
close to that of unmodified DNA (Figure 2.13, arrow B).  A small residual amount of 
unbound DNA remains (lanes 4-9, arrow A).  For the densitometry analysis, the amount 
of protein required for each shift of DNA was divided in half as the concentration of DNA 
was 2x (or 0.52 µM).  It was assumed that twice as much protein was required for twice 
as much DNA, thus for half the amount of DNA (0.26 µM) only half the amount of 
protein would be required to create the same DNA shifts. 
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 bottom of 
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Figure 2.13: 22G4 with p50BD. 
Lanes 1-10: dsDNA (concentration is 2x, 0.52 µM) + p50BD (0, 0.471, 0.942, 1.414, 
1.885, 2.356, 2.827, 3.298, 3.769 and 7.068 µM protein) 
 
 
Table 2.3: Densitometry for 22-mer κB sequences and p50BD 
 % of DNA shifted by p50BD 
p50BD (µM) Control 8-oxoG1 8-oxoG2 8-oxoG3 8-oxoG4
0 2.208424 1.060578 2.955006 0.732107 1.577256
0.236  21.78485
0.471 36.58448 4.076286 57.51619 4.303915 47.78349
0.707  72.54122
0.942 83.29771 23.92229 83.51295 11.83553 91.22873
1.178  99.82418
1.414 91.06419 23.92229 99.06544 13.11185 
1.885 52.26755 12.27109 
2.356 52.26755 14.74826 
2.827 57.80033 14.90688 
3.298 60.45242 12.75896 
3.769 90.70031 22.96632 
4.241 100  
 
Lane 1 corresponds to zero µM p50BD protein on the gels shown from Figure 2.9 to 
Figure 2.13; the pattern was that lane 2 up to lane 10 increased in increments of ~ 0.471 
µM (200 ng) p50BD protein.  The analyses of the densitometries for only Figure 2.9 were 
rounded up to the nearest hundred of ng of protein for Kapp analysis which changed the 
µM concentrations; for example 194 ng protein became 200 ng (0.457 µM  0.471 µM), 
and 388 ng became 400 ng (0.914 µM  0.942 µM), and 582 ng became 600 ng (1.371 
µM  1.414 µM).  The analysis of Figure 2.13 assumes that twice the concentration of 
modified DNA requires twice the concentration of protein to elicit the shifts.  For the Kapp 
calculations and Table 2.3, the values for the protein concentrations are divided in half 
and reported in µM values. 
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Interaction of the 30-mer κB DNA control oligonucleotide sequence with p50BD: 
For Figure 2.14, a greater than 90% shift of the DNA is accomplished using 0.457 
µM p50BD protein (lane 3 as compared to zero shift from lane 1, no protein) and a 
complete shift with 0.914 µM protein (lane 4).  These concentrations of protein required 
to shift similar amounts of 22-mer κB DNA are exactly the same; 0.914 µM protein are 
required to have a 100% shift for the 22-mer control (Figure 2.9, lane 3).  However, in no 
situation with the 30-mer κB DNA was there ever a second DNA shift due to monomeric 
and dimeric protein binding interactions.  Excess protein confirms the 100% shift of 0.914 
µM p50BD (lanes 4 – 7). 
 
        
           1      2      3       4       5      6      7 
bottom  
of wells 
B  
A  
Figure 2.14: 30-mer control κB DNA and p50BD. 
Lanes 1-7: dsDNA + p50BD (0, 0.229, 0.457, 0.914, 1.371, 1.828, and 2.285 µM protein). 
 
Interaction of the 30-mer κB DNA modified at guanine positions G1, G2, and G3 
sequences with p50BD: 
The side-by-side comparison shows that the presence and location of the 8-
oxoguanine modification completely determines the p50BD protein apparent binding 
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affinity (Figure 2.15).  This figure shows clearly that 30-mer G3 modification has the 
poorest binding compared to the 30-mer control, G1, and G2 modified DNA. 
 
1 2 3 4 5 1 2 3 4 5 1 2 3 4 5 1 2 3 4 5
Figure 2.15: 30-mer dsDNA (all 2.6 µM); Control, 8-oxo G1, G2, & G3 with p50BD 
Lanes 1-5: 0, 0.457, 0.914, 1.371, and 1.828 µM p50BD. 
 
 
The 22-mer 8-oxoguanine modified at position G2 κB DNA showed monomeric 
p50BD protein binding at 100% and then dimeric protein binding at higher concentrations 
of protein (2.356 µM protein, lane 6, Figure 2.11).  Figure 2.15 for 8-oxoguanine 30-mer 
modified at position G2 does not include a lane of 2.356 µM protein, the highest amount 
of protein used was 1.828 µM; it is possible that a higher concentration of protein (~2.356 
µM) could elicit a dual banding of dimeric and monomeric protein.  It is feasible that the 
flanking regions of the oligonucleotide for the 22-mer as compared to the 30-mer 
influence the binding specificities for monomer versus dimer for modified κB DNA.   
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Table 2.4: Densitometry for 30-mer κB sequences and p50BD 
 % of DNA shifted by p50BD 
p50BD (µM) 30-mer control 30-mer G1 30-mer G2 30-mer G3
0 0 0 0 0
0.457 59.4802 1.0042 1.07666 0
0.914 99 29.413 9.95949 2.0361
1.371 99.9 31.989 22.8742 3.1557
1.828 53.371 35.5561 3.4296
 
p50BD protein-free sample corresponded to lane 1 on the gels shown in Figure 2.14 and  
Figure 2.15; the pattern followed that lane 2 up to lane 10 increased in increments of  
0.457 µM p50BD protein, such that lane 2 was 0.457 µM, lane 3 was 0.914 µM and so 
forth as indicated in the figure legends.  
 
 
Interaction of the 30-mer κB DNA sequences with p50H67A, mutant protein: 
 
 
bottom  
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B  
A 
Figure 2.16: 30-mer control κB DNA and p50H67A. 
Lanes 1-10: DNA (0.26 µM) + p50H67A (0, 0.457, 0.914, 1.371, 1.828, 2.285, 2.742, 
3.199, 3.656, and 4.11 µM protein).  
Lane 12: single stranded control DNA, 2x concentration (0.56 µM). 
 
The mutant p50 protein, p50H67A, was incubated with 30-mer κB DNA 
sequences.  A nearly 100% shift of the DNA is accomplished using 2.356 µM p50BD 
protein (lane 6) as evaluated by Kapp (Table 2.5, page 46).  Indeed, a 2.5-fold increase is 
required in p50H67A protein amount as compared to p50BD protein to fully shift all 
DNA (compare Figure 2.14 to 2.16).   
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Interaction of the 30-mer κB DNA sequence modified at position G1 with p50H67A: 
 
B  
A  
Figure 2.17: 30-mer G1 κB DNA and p50H67A. 
Lanes 1-10: dsDNA (0.26 µM) + p50H67A (0, 0.457, 0.914, 1.371, 1.828, 2.285, 2.742, 
3.199, 3.656, and 4.11 µM protein) 
Lane 12: single stranded control DNA, 2x concentration (0.56 µM) 
 
Gel shifts of the 8-oxoguanine modification at G1 for the 30 base pair oligomer 
Figure 2.17 shows that the protein binds better to the control strand than to the modified 
strands.  There appears to be nearly a 100% gelshift by 2.827 µM p50H67A incubated 
with G1 modified 30-mer compared to 2.356 µM protein required to shift unmodified 30-
mer DNA.  Table 2.5 indicates that the binding of p50H67A is slightly worse for the G1 
8-oxoguanine modified than that for the 30-mer control DNA. 
If the histidine in position 67 is critical for binding class I κB DNA sites, a 
difference in binding affinity should be observed between the 30-mer control with p50BD 
and p50H67A (see Figures 2.14 and 2.15).  The difference in binding affinity was around 
2.5-fold, which seems indicative of a role for histidine 67 in binding to the consensus 
sequence.  The mutant was not pursued further; the results indicated that the importance 
of the mutation, shown in terms of binding affinity, was not as dramatic as it would have 
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been if the histidine position at 67 was critical for making bonds to non-modified and 
modified κB DNA.   
 
Table 2.5: Densitometry for 30-mer κB sequences and mutant p50H67A 
 % of DNA shifted by p50BD 
lane p50H67A (µM) control 8-oxoG1 
1 0 2.6224 0 
2 0.457 29.1754 0 
3 0.914 67.3939 0 
4 1.371 87.2181 14.3406 
5 1.828 87.9168 35.6470 
6 2.285 99 35.6470 
7 2.742 99 99 
 
From Table 2.5,  zero µM p50H67A protein corresponded to lane 1 on the gels shown in 
Figure 2.16 and  Figure 2.17; the pattern followed that lane 2 up to lane 10 increased in 
increments of  0.457 µM p50BD protein, such that lane 2 was 0.457 µM, lane 3 was 0.914 
µM and so forth as indicated by the figure legends.   
 
The NF-κB proteins are flexible in their binding; this is demonstrated by the 
mutant p50H67A protein, which was capable of binding the κB DNA consensus site.  
Nonetheless, it is known that these small differences in binding affinities for κB 
sequences can have an impact on the expression of genes.  Perhaps the importance of the 
different binding affinities can only be seen in vivo.  This leaves the door open to the 
possibility that the role of the DNA sequence, any modifications, and DNA conformation 
has an important regulatory responsibility in gene expression with the NF-κB protein 
 
 
 
 
 
 47
Discussion:  
The p50 binding domain, residues 23 to 366, and a single amino acid mutation of 
histidine 67 to alanine 67 were cloned as an N-terminal his6-tagged protein.  These 
proteins were expressed and purified as active proteins. 
The effect of 8-oxoguanine at each guanine site in the consensus sequence of κB 
DNA on the binding affinity of p50BD was determined on a 22-mer and a 30-mer double-
stranded DNA oligonucleotide containing the NF-κB binding site with modifications at 
guanine sites (Figure 2.9 – Figure 2.13).  The addition of a carboxyl moiety at position 8 
on guanine (creating 8-oxoguanine) changes the binding affinity for the κB sequence.  It 
has been seen that the non-modified control binds the p50 binding domain homodimer 
better than certain 8-oxoguanine modified κB DNA at specific sequences.  Both 8-
oxoguanines G2 and G4 modified DNA binds with an affinity better than that of non-
modified control κB DNA.  The 8-oxoguanine G2 has an interesting binding pattern with 
the presence of dual binding bands (Figure 2.11) which indicates that monomeric p50BD 
binds initially, and that at higher protein concentrations, the p50BD dimer can bind.  It 
has been proposed that the loss of a hydrogen bond donor-acceptor pair from the arginine 
R59 of p50BD to the N7 (modified) of 8-oxoguanine G2 accounts for the loss of the p50 
binding affinity (see Figure 2.2, page 23). 
Earlier work investigated the apparent dissociation constants (Kapp, Table 2.6, p49) 
of a full length dimeric p50 protein (Promega) with 8-oxoguanine modified κB sites.  
From the early work, the relative Kapp for the unmodified control was found to be 0.672 
µM with little change in the 50% binding affinity observed with the 8-oxoguanine 
modifications at G2 and G4 for the 22-mer.  Additionally, the 8-oxoguanine modification 
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at G3, showed a nearly 4-fold decrease in Kapp for binding of the p50 subunit to this 
modified DNA sequence versus the unmodified DNA sequence.  Earlier work with 8-
oxoguanine G3 modified κB DNA and lowered p50 binding affinity suggested that this 
modification can cause recognition loss of one of the κB DNA half sites.9  This 
relationship appears to be true for the truncated p50 monomeric protein, p50BD, as well. 
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Figure 2.18: Data taken from Table 2.3.  Kapp binding for 22-mer κB DNA 
oligonucleotide sequences and p50BD.  There are no error bars as the one gel considered 
the ‘best’ of each sequence was analyzed by densitometry. 
 
 
It was found that the clone p50BD protein behaved in a manner analogous to the 
full length Promega p50 protein with the same oligomer sequences, with the exception of 
the 22-mer modified at G1.  In fact, the p50 binding domain-only protein had apparent 
binding affinity of 0.605 µM compared to the binding affinity of 0.672 µM for full-length 
dimer protein (see Table 2.6) for control κB DNA.  With modified κB DNA sequences, 
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the truncated monomeric p50 protein, p50BD, retains the ability to interact in a manner 
similar to the full-length dimeric p50 protein.  The fewer number base pairs in the 
engineered protein (consisting of the binding domain only), consequently results in fewer 
potentially stabilizing amino acid residues.  However, the lack of a few amino acid 
residues apparently does not greatly impact the protein’s stability upon binding κB DNA. 
 
Table 2.6:  Binding affinities of the 22-mer control and 8-oxoguanine modified DNA 
with p50 binding domain and p50 (whole protein). p50 data taken from Hailer-Morrison, 
et al (2003) Biochem. 42, 9761-9770.9
Oligonucleotide   p50 binding domain only  
Kapp binding affinity (µM)* 
p50 (Promega, dimer)  
Kapp binding affinity (µM)* 
Control 0.605 0.672  +/- 22  
8-oxo-dG at G1  1.849 0.283  +/- 7     
8-oxo-dG at G2 0.405 0.644  +/-35    
8-oxo-dG at G3  10.69 2.340  +/- 40    
8-oxo-dG at G4 0.498 0.550  +/- 35   
* The Kapp for the non-modified control and 8-oxoguanine modified oligonucleotides 
were determined graphically as the point where the percent bound was 50%. 
 
For binding affinity, a lower number indicates a better binding of protein to DNA, 
and a higher number indicates a poor affinity of protein for DNA.  The binding affinities 
above in the column “p50 binding domain only” were calculated assuming that the molar 
ratio of dsDNA to protein was 1 to 1 as compared to the earlier work with dsDNA to full-
length p50 protein ratio at 1 to 2.  For half-site binding, when comparing the 22-mer 
control DNA binding with p50BD to the binding of modified oligonucleotides with 
p50BD, it was seen that the binding affinity was best for the 8-oxoguanine modified at 
G2, then G4, and then followed closely by the control DNA.  When comparing p50BD 
protein binding to control κB DNA (Figure 2.9, Kapp = 0.605 µM) with p50BD with 22G1 
modified κB DNA (Figure 2.10, Kapp = 1.849 µM) it is seen that the truncated p50BD 
protein has a poorer affinity for modified DNA at the G1 position.  This result is in direct 
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contrast to that of the whole p50 protein; 8-oxoguanine modified at G1 had a better 
binding affinity (0.283 µM) than control DNA (0.672 µM) for the Promega p50 dimer.   
The EMSA for 22G2 showed two DNA-protein binding bands with a higher 
concentration of protein (Figure 2.11) due to the p50BD binding as either a monomer or a 
dimer to the κB DNA.  The results indicate that the protein binds independently as a 
monomer for lower p50BD—DNA concentrations (Figure 2.11, arrow B)  however, given 
enough p50BD protein, ~ 2.356 µM, the 22-mer 8-oxoguanine G2 modified DNA will be 
bound at both κB sites with two p50BD monomers – giving a dimer protein (see arrow C, 
Figure 2.11).  A 100% shift was observed with the putative monomeric protein.  
Integration was based on arrow B, the monomer; further calculations for higher protein 
concentration integration involved the addition of the two shifted bands (arrow B and C, 
Figure 2.11).  Work with the whole protein indicated no such dual banding with 8-
oxoguanine modified at G2, however the concentration of protein was 2 µM or less, 
which is perhaps not enough protein to cause a dual banding. 
The EMSA for the 22G3 showed that the modification negatively impacts DNA 
binding, with an extrapolated by linear regression Kapp of 10.69 µM (Figure 2.12).  This 
loss of binding, reflected in a higher Kapp values, was proposed to be due to loss of the 
half site of the κB DNA.  The greatest percentage of protein bound to DNA was 
determined to be 23%, thus the Kapp at 50% bound DNA-protein was never achieved and 
was extrapolated graphically (50% bound DNA-protein = 4.318603143x + 3.820307386, 
where x = Kapp (µM)).  The poor binding with 8-oxoguanine modified at G3 is in 
agreement with the trend seen with whole p50 protein.
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Comparing the 22-mer modified G4 (Figure 2.13) to control κB DNA (Figure 
2.9), it was observed that the modified κB DNA requires less p50BD protein to exact a 
complete shift. This is based on the assumption that twice the concentration of DNA 
requires twice the concentration of protein to gel shift.  The Kapp values were quite close 
for binding affinities for the G4 and the control; more gels evaluated by densitometry 
could possibly determine if this relationship is valid and that there is a slight but distinct 
difference between the two oligonucleotide sequences. 
Taken as a whole, these results indicate that the recognition of κB DNA by p50BD 
decreases with 8-oxoguanine modification except for at the G2 and G4 positions.  
Furthermore the loss in binding affinity is most dramatically seen with modification at 
G3.  The 8-oxoguanine modification has the least amount of impact with modifications at 
G4 having a Kapp similar to the Kapp for control.  The most interesting interactions 
between DNA and protein are seen with the 8-oxoguanine G2 modification where the 
protein can be visualized binding as both a monomer (Figure 2.11, arrow B) and as a 
dimer (arrow C). 
 
DNA-p50H67A (mutant protein) interactions 
The binding of p50H67A with 30-mer κB control DNA was performed to 
determine the importance of the histidine in position 67 of the human p50 protein.  A 
difference was observed between the binding of p50BD protein and p50H67A protein to 
κB DNA (see Figures 2.14 and 2.16); the p50BD has greater affinity for the 30-mer 
control sequence and the 8-oxoguanine modified G1 sequence than the p50H67A 
(Kappp50BD = 0.386 µM versus Kappp50H67A = 0.707 µM for control κB DNA).  The 
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histidine in p50BD protein makes potential contacts with the G1 which accounts for the 
difference in binding of 1.755 µM versus 2.391 µM when comparing p50BD and 
p50H67A binding to 8-oxoguanine modified at position G1. The histidine to alanine 
mutation allows the p50H67A protein to mimic the p65 (RelA) protein, which prefers a 9 
base pair sequence.  The anticipated result was that the mutant p50H67A would not bind 
the 30-mer κB DNA sequence or would bind extremely poorly and would be reflected in a 
high numeric value for the Kapp.  Thus the slightly diminished binding affinity was not 
significant enough to confirm that the histidine (H67) is critical for binding modified κB 
oligonucleotides.  Perhaps the binding affinity would be significant in vivo. 
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Figure 2.19: Data taken from Table 2.4 and Table 2.5; Kapp for 30-mer κB DNA 
oligonucleotide sequences with p50BD or p50H67A.  No error bars were included as only 
the one best gel of each sequence was analyzed by densitometry. 
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Table 2.7:  Binding affinities of 30-mer control and 8-oxoguanine modified DNA with 
p50BD (binding domain) and p50H67A (mutant) 
P50BD P50H67A 
Oligonucleotide 
 
Kapp binding affinity 
(µM)* 
Oligonucleotide 
 
Kapp binding affinity 
(µM)* 
Control 0.386 Control 0.707 
8-oxo-dG at G1  1.755 8-oxo-dG at G1  2.391 
8-oxo-dG at G2 2.690 8-oxo-dG at G2 n/d 
8-oxo-dG at G3  22.94 8-oxo-dG at G3  n/d 
* The Kapp for the non-modified control and 8-oxoguanine G1 modified oligonucleotides 
were determined graphically as the point where the percent bound was 50%.  The Kapp for 
the 8-oxoguanine modifications to G2 and G3 bound with p50BD were extrapolated by 
linear regression.  n/d indicates that the relationship was not determined. 
 
The p50H67A was also able to bind the 30-mer κB DNA 8-oxoguanine modified 
at position G1.  It was predicted that the 8-oxoguanine containing DNA modified at G1 
would bind the mutant protein differently as compared to the unmodified κB DNA.  8-
oxoguanine, with its increased number of donor/acceptor contacts (see Figure 1.3 A & B, 
page 7) could potentially stabilize protein bonding to DNA modified at position G1 by 
hydrogen bond/electrostatic contacts to the mutant protein.   The possible areas for 
contact include the carboxyl moiety of the protein backbone from alanine 67 to glycine 68 
as a hydrogen bond acceptor from the hydrogen of N7 of 8-oxoguanine and arginine 59 
NH2 as hydrogen bond donor to the carboxy at C8 of 8-oxoguanine.  The values for the 
mutant protein binding to 8-oxoguanine G1 were expected to have lower Kapp values 
indicating a greater binding affinity as compared to the Kapp values for 8-oxoguanine 
binding to p50BD.  This predicted relationship was not observed, and it is possible that 
the 8-oxoguanine at G1 does not make the predicted contacts to protein to stabilize 
binding.  A crystal structure of the mutant protein bound to κB DNA (non-modified and 
modified) would clarify the DNA-protein interactions. 
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It was seen that the binding affinity for the p50BD versus p50H67A in binding to 
control κB DNA was around 2 -fold difference.  Taking all the information together, these 
results suggest that the histidine H67 is important in binding class I κB DNA.  While 
conserved for this consensus sequence, this amino acid is not shown to be critical for 
binding a small oligonucleotide sequence, as there is a level of binding visible (Figure 
2.16 versus Figure 2.14).  This could be the result of the inherent flexibility of the protein 
which still allows for DNA binding even if the sequence is not ideal (containing the class 
I κB site of 5’-GGG RN-3’ half-site, where R is purine and N is any nucleotide).  
Comparing the 8-oxoguanine modifications made to κB DNA and control κB DNA, the 
results indicate that the p50BD protein binds better to non-modified DNA and perhaps 
modifications to DNA by an oxidative mechanism is not necessarily a secondary form of 
transcriptional regulation in the genome.  Clarifications to this theory could be determined 
by using a histone-wrapped full length gene with this exact consensus sequence κB DNA 
to mimic in vivo DNA-protein actions.  It is possible that the DNA-wrapped histone 
confers protective shielding to sites on DNA susceptible damage and/or protein binding. 
 
 
 
 
 
 
 
 55
                                                                                                                                                  
1 Sen, R. and Baltimore, D. (1986) Multiple nuclear factors interact with the 
immunoglobulin enhancer sequences. Cell 46(5), 705-716. 
2 Aggarwal, B.B. (2004) Nuclear factor-κB: The enemy within. Cancer Cell 6, 203-208. 
3 Baldwin, A. S. (1996) The NF-κB and IκB proteins: new discoveries and insights. Annu. 
Rev. Immunol. 14, 649-681. 
4 Chytil, M. and Verdine, G.L. (1996) The Rel family of eukaryotic transcription factors. 
Curr. Opin. Struct. Biol. 6(1): 91-100. 
5 Huang, D.-B., Phelps, C.B., Fusco, A.J., and Ghosh, G. (2005) Crystal structure of a free 
κB DNA: insights into DNA recognition by transcription factor NF-κB. J. Mol. Biol. 346: 
147-160. 
6 Ghosh, G., Van Duyne, G., Ghosh, S., and Sigler, P.B. (1995) Structure of NF-κB p50 
homodimer bound to a κB site. Nature 373, 303-310. 
7 Müller, C.W., Rey, F.A., Sodeoka, M., Verdine, G.L., and Harrison, S.C. (1995) 
Structure of the NF-κB p50 homodimer bound to DNA. Nature 373, 311-317. 
8 Gilmore, T.D., Koedood, M., Piffat, K.A., and White, D.W. (1996) Rel/NF-κB/IκB 
proteins and cancer. Oncogene 13, 1367-1378. 
9 Hailer-Morrison, M.K., Kotler, J.M., Martin, B.D., and Sugden, K.D. (2003) Oxidized 
guanine lesions as modulators of gene transcription.  Altered p50 binding affinity and 
repair shielding by 7,8-dihydro-8-oxo-2’-deoxyguanosine lesions in the NF-κB promoter 
element. Biochemistry 42, 9761-9770. 
10 Glover, D.M. DNA cloning: a practical approach, Volume 1 1985, Oxford: IRL Press. 
 56
CHAPTER 3 
DNA-protein with chromium exposure could lead to crosslinking: 
Background on previous work: 
The five different κB DNA sequences, non-modified and modified at guanine 
positions, for the 22-mer, 5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’, have been 
shown to have discrete binding affinities for the p50 binding domain protein and 
p50H67A protein. The 30-mer oligomer sequence, 5’- TCC GCT G1G2G3 G4AC TTT 
CCG CGG AGA CTC TAG-3’, contains a slightly different flanking regions, however 
the consensus sequence (bold) remains the same.  These oligonucleotide κB DNA 
sequences of 22 and 30 base pairs were used to explore the complex interactions of 
oxidized DNA and p50BD protein with chromium treatment. 
Previous work has established that, by reduction and oxidation potentials, it is 
energetically favorable to further oxidize 8-oxoguanine-modified DNA while reducing 
chromium(VI) if the two species are together in solution.  If water acts as a nucleophile, 
an additional oxidative event generates guanidinohydantoin (Gh) and 
spiroiminodihydantoin (Sp) (see Figure 1.5, page 9).  When protein is bound to modified 
DNA it can potentially exclude or out-compete the water.  Thus while chromium is 
reduced in an oxidative event, and protein acts as a nucleophile, the oxidation of DNA 
could crosslink the DNA—protein together in a covalent bond.  This covalent 
crosslinking of DNA and protein would establish a new mode of chromium toxicity with 
damaged DNA. 
Amino acids of interest in forming covalent bonds with any of the four different 
8-oxoguanine modified bases in the κB DNA oligonucleotide are at the consensus site of 
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the p50BD protein; these include arginine 57, arginine 59, tyrosine 60, histidine 67, 
glutamate 60, and lysine 244 (Figure 3.1, taken from Huang et al., and 1SVC from the 
Protein Data Bank; murine p50 - amino acids relative positions are three less base pairs 
compared to human p50).1   
 
G4 
G3 
G2 
G1 
Figure 3.1:  Half site binding of p50 with DNA (4 guanine sequence) 
Taken from Huang, et al. (2003) Proc. Natl. Acad. Sci. 100, 9268-9273. 2,3
 
 The potential areas of binding include, but are not limited to the G1 of κB DNA 
with histidine 67 (H64) of p50BD protein and G4 of κB DNA with lysine 244 (K241) of 
p50BD protein (Figure 3.1).  The functional group of histidine is the imidazolium moiety, 
with two nitrogens available for chemical interactions.  Histidine has a pKa = 6.0, which 
means that at pH 6.0 half of the molecules are charged, and histidine is neutral on the 
basic edge of physiological pH range, 6.5 to 7.6.4, 5  Thus histidine often contributes 
 58
hydrogen bonds in enzymatic reactions.  The lysine is available to form a Schiff base 
through the distal amine depending on solution conditions.  At physiological pH it is 
positively charged with a pKa = 10.54.  The arginines, with their available nitrogen 
groups, are in close proximity to guanines 2 and 3 (G2 and G3, Figure 3.1).  These amino 
acids are also able to form Schiff base bonds with the pKa = 12.48 for the guanidinium 
moiety.4
The amino acids listed above have the potential to act as nucleophiles on 8-
oxoguanine modified DNA competing with water which is a relatively poor nucleophile.  
The nucleophile can attack the C5 position on the guanine (see Figure 2.2, page 23) and 
attach to the nucleic acid moiety. 
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Materials and methods: 
Deoxyribonucleotides.  Unmodified oligonucleotides with the κB consensus sequence 
were obtained from IDT DNA (Coralville, IA).  Modified 22-mer DNA sequences 
containing an 8-oxoguanine in the NF-κB protein p50 homodimer consensus sequence 
(5’-AGT TGA G1G2G3 G4AC TTT CCC AGC C-3’, where the bold bases indicate the 
consensus sequence and the G1-4 indicate positions of 8-oxoguanines in the recognition 
sequence) were obtained from TriLink Biotechnologies (San Diego, CA).  Modified 30-
mer DNA sequences containing the sequence 5’- TCC GCT G1G2G3 G4AC TTT CCG 
CGG AGA CTC TAG -3’ (again the bold bases indicate the consensus sequence and the 
G1-4 indicates positions of 8-oxoguanines in the recognition sequence) were also obtained 
from TriLink Biotechnologies.  HPLC purification of the 22-mer oligonucleotide strands 
was performed using a Dionex DNAPac PA-100, 4 mm x 250 mm anion exchange 
column.  Elution was accomplished with a linear gradient of 90% mobile phase A (10% 
aqueous acetonitrile) and 10% mobile phase B (1.5 M ammonium acetate (pH 6.2), 10% 
acetonitrile) to 100% mobile phase B over the course of 22 minutes.  The 30-mer 
oligonucleotide was purified in a similar manner, however mobile phase A also contained 
500 mM NaCl and elution was accomplished with a linear gradient of 90% A and 10% B 
to 100% mobile phase B over 30 minutes.  Column elutions of oligonucleotides were 
observed by diode array at 268 nm.  The single-peak elution of oligomer was evaporated 
to remove the volatile acetonitrile, eluted through a BioRad chromatography column 6 
and stored at -20˚C until needed for testing.  The NaCl from the 30-mer oligonucleotides 
was removed by elution through a BioRad chromatography column 30.  Standard 
methods were employed to 5’- 32P end-label specific oligomers.  The control or 8-
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oxoguanine containing single stranded DNA was incubated with polynucleotide kinase 
and 10 µCi of 32P-γ-ATP for 30 minutes.  Column elutions with a Micro Bio-Spin 6 
chromatography column from BioRad (Hercules, CA) removed the enzyme and 
unincorporated nucleotides.  The radiolabeled single stranded DNA was annealed to 
complement DNA by heating to 95˚C and slowly cooling 1˚C / 1 minute using a Peltier 
Thermal Cycler from MJ Research (BioRad, Waltham, MA). 
NF-κB p50BD Transcription Factor Protein.  The p50 binding domain sequence from 
residues 23 to 366 was created as described in chapter 2 by cloning into the pPROEX 
HTa II plasmid to give the protein as an N-terminal His6-tagged protein. 
Protein purification.  The expression plasmids, in BL21 (DE3) cells, were grown to an 
OD600 of 0.3-0.6 at 37˚C in LB media containing 25 µg/mL ampicillin, as the pPROEX 
HTa contains an ampicillin resistance cassette.  Cells were induced with IPTG to a final 
concentration of 0.1 mM and incubated for 4 hours at 37˚C.  Cells were then harvested by 
centrifugation at 4˚C and 5,000 rcf, and frozen at -20˚C for later use.  After thawing on 
ice, cells were lysed using the BugBuster® protocol and reagent (Novagen, 5 mL reagent 
per gram wet cell paste), lysozyme (Sigma, 0.5 mg per gram wet cell paste), Benzonase 
nuclease (Novagen, 1 µL per mL BugBuster® reagent), and protease inhibitor cocktail 
(Roche, 1 tablet dissolved in 2 mL H2O, use 0.2 mL per 5 mL extraction reagent).  Cell 
lysate was filtered through a Ni-NTA column (Qiagen).  Protein was washed with 
Solution A and B (50 mM NaH2PO4, 300 mM NaCl, with 10 mM and 20 mM imidazole 
respectively) and eluted with Solution C (50 mM NaH2PO4, 300 mM NaCl, 250 mM 
imidazole).  The elution fraction was de-salted using a Microcon YM-10 and eluted into 
protein storage buffer (20 mM HEPES, 50 mM NaCl, pH 7).  An aliquot was reserved for 
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BCA protein concentration analysis (BCA kit, Pierce, Rockford, IL), and the remaining 
sample was diluted in half with protein storage buffer containing 40% glycerol, aliquoted 
into sub-samples, and stored at -80˚C. 
Chromium(V)-Salen.  Three mg chromium(III)-Salen were dissolved in 300 µL dry 
acetonitrile (20 mM chromium(III)-Salen).  Three mg iodosyl benzene were added to the 
solution and incubated for 30 minutes.  The solution (chromium(V)-Salen) was diluted to 
appropriate concentrations and used immediately. 
HPLC shift Assay.  DNA-protein binding reactions were performed using 50 µM 5’-DNA 
which had been annealed to its complement to create double stranded DNA (dsDNA) and 
approximately 32 µg p50BD protein.  The reaction buffer for the DNA-protein binding 
was 5 µL Buffer A (20 mM HEPES, 50 mM NaCl, pH 7) and Buffer B (Promega: 20% 
glycerol, 5 mM MgCl2, 2.5 mM EDTA, 2.5 mM DTT, 250 mM NaCl, 50 mM Tris-HCL, 
pH 7.5, 0.25 mg/ml poly(dI-dC)) to a total volume of 100 µL.  The DNA and protein 
were allowed to react for 20 minutes before chromium(V)-Salen was added (at varying 
ratios to DNA, frequently 1:1,1:2, 1:5, 1:10, and 1:100) and incubated for 30 minutes at 
room temperature.  A cation exchange column, engineered by glass pipette, glass wool, 
15 mg CM-Sephadex C-25-120 Resin (Sigma), and 200 µl H2O, removed the cationic 
chromium from the DNA-protein solution.  The DNA-protein sample was dried to 15 µL 
for sample injection onto the HPLC.  The concentrated sample was injected onto a 
Dionex DNAPac PA-100, 4 mm x 250 mm anion exchange column.  Elution was 
accomplished with a linear gradient of 90% mobile phase A (10% aqueous acetonitrile) 
and 10% mobile phase B (1.5 M ammonium acetate (pH 6.2), 10% acetonitrile) to 100% 
mobile phase B over the course of 22 minutes.  Later HPLC shift assays used only 
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reaction Buffer A with concentrated p50BD protein and DNA to a total volume of 10 µL 
after chromium(V)-Salen addition.  The sample cleanup on the cation exchange column 
and HPLC sample injection was performed as described above. 
Electromobility Shift Assay (EMSA or gelshift).  DNA-protein binding reactions were 
performed using 2.6 µM 5’-32P radioactive-labeled DNA which had been annealed to its 
complement to create double stranded DNA (dsDNA).  The reaction buffer for the DNA-
protein binding was 300 mM NaH2PO4.  When carrying out an EMSA on a 
polyacrylamide gel; either a native 4% polyacrylamide gel was poured (with or without 
urea), or a 6% Invitrogen pre-poured DNA retardation gel was used.  The denaturant used 
was 8 M urea added to the sample or added to the gel, heat, a combination of both.  The 
DNA and protein were allowed to react for 20 minutes before running on the gel.  
Additionally, glycerol (1 µL, 40%) was added to all reaction mixes to increase density 
and help with sample loading.  Unless a free well was available for dye only, the sample 
‘DNA only’ was the only well to have loading dye added in order to minimize any 
interference of the dye with the DNA and protein binding interactions.  The gels were run 
at 250-300 V for ~10 minutes.  The gel shifts were analyzed by autoradiography (Kodak). 
Analysis of Reductively-trapped Schiff Base complexes of hOGG1.  The chromium(V)-
Salen treated, 32P-labeled dsDNA (2.6 µM) was incubated with hOGG1 (15 nM, New 
England Biolabs) in 10 µL reaction buffer (20 mM Tris-Cl (pH 8.0), 1 mM EDTA, 1 mM 
DTT, 100 µg/mL BSA, 3 µL H2O) in the presence of 65 mM NaCNBH3 at 37˚C for 60 
minutes.  Glycerol (1 µL, 40%) was added to the sample.  The gel shifts was analyzed as 
described above.  hOGG1 (38 KDa) is of comparable size to the p50BD protein (42.4 
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KDa) for comparison of crosslinking.  Visualization of this reductively-trapped crosslink 
will indicate if it is possible to visualize oxidatively-trapped or crosslinked DNA-protein. 
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Figure 3.2: Borohydride trapping of lysine 249 on hOGG1 
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Results 
Covalent bonds are more resistant to degradation, meaning heat, urea, or similar 
conditions that disrupt other bonds (ionic, van der Waals, or hydrogen bonds), and for 
observation by HPLC these covalently bonded moieties could elute later or travel on a 
PAGE gel as a single, larger complex than the DNA alone.  An electrostatic bond of 
DNA--protein will not remain as a single peak in HPLC system nor as a single DNA-
protein band under rigorous denaturing conditions in a gel system. 
The HPLC purification provides an elegant method to separate forms of modified 
DNA.  Modifications to DNA such as Gh and Sp can be resolved from 8-oxoguanine 
even at higher ratios of 1:100, DNA : chromium (Figure 3.3).  Therefore modifications to 
DNA, such as a covalent protein linkage could also be resolved on HPLC as compared to 
an 8-oxoG modification.6  Figure 3.3 shows Gh/Ia tautomers at peaks 1 and 2, the 8-oxoG 
at peak 3, peak 4 is Sp, and peak 5 is an unidentified further oxidized species. 
  
8-oxo DNA 
 
Figure 3.3: HPLC trace of water as nucleophile on 8-oxoguanine exposed to chromium 
Trace Blue = 8-oxo DNA, Trace Red = Cr(V)-Salen treated 8-oxoguanine. 
Peaks 1 & 2 – Gh/Ia, tautomers, Peak 3 – 8-oxoG, Peak 4 – Sp 
Peak 5 – further oxidized 8-oxoGox, Ghox or Spox, ratio of DNA to Chromium is 1:100. 
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In Figure 3.4, for the ‘DNA + p50BD + chromium’, the DNA was incubated with 
p50BD protein for 20 minutes before a 30 minute chromium(V)-Salen exposure.  The 
electrostatically bonded ‘DNA + p50BD’ (red) looks very similar to the ‘DNA + p50BD 
+ chromium’ (magenta); crosslinking would create a system resistant to degradation, and 
covalently bonded DNA–protein should elute at a different time than electrostatically 
bonded DNA--protein.  Perhaps the p50BD protects the oxidized DNA from further 
oxidation or there was not enough protein to successfully bind and shift the DNA on the 
HPLC, or it was lost in the clean-up process.  The trace of ‘8-oxo DNA + chromium’ in 
Figure 3.4 (green) is the same sample  composition as the ‘8-oxo DNA + chromium’ 
from Figure 3.3 (red), however, the DNA:Cr ratio is 1:1, the peaks for Gh/Ia appear less 
resolved and no Sp peak is detected.  A higher ratio of chromium, such as 1:2 DNA to 
chromium, would create more Gh/Ia and Sp for improved peak resolution.  The DNA 
sample with protein and chromium is not distinctly different than the DNA + chromium 
sample, however, previous work at higher chromium concentrations indicated that the 
protein shields the DNA from chromium damage.7  It is possible that the cation exchange 
column contributed to a small loss of DNA in samples placed on the HPLC.  If a covalent 
crosslink had occurred and was detected by the HPLC, it is possible that the complexes’ 
charge might be different thus there would be a DNA-p50BD complex eluting at a 
different time in the magenta trace, and this was not observed. 
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Figure 3.4: HPLC trace of 8-oxoguanine with and without protein, and with chromium 
Controls: Blue-ds-8-oxoguanine DNA only; Red- 8-oxoguanine dsDNA + p50BD; 
Green- 8-oxoguanine dsDNA + chromium; 8-oxoguanine DNA + p50BD;  
Sample: Magenta- - 8-oxoguanine DNA + p50BD + chromium; 
  * Initial amounts of DNA were the same, HPLC traces are offset for comparison 
 
 It was determined that the HPLC, as set up with an anion exchange column, was 
not the optimal setting for determining covalent DNA-protein bonding.  One system that 
required less DNA and less protein was a polyacrylamide gel using radiolabeled DNA.  
Electrophoretic gel shift assays of DNA-protein were performed to determine Kapp values 
for binding affinities for the five 22-mer modified and unmodified κB DNA sequences 
(chapter 2). 
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Figure 3.5: Gel comparison of control vs. 8-oxoG DNA with and without chromium 
Lanes 1-6 unmodified DNA, Lanes 7-12 8-oxo G1 DNA 
L R the samples are DNA, DNA + protein, DNA + protein with urea, DNA + 
chromium, DNA + protein + chromium, and DNA + protein + chromium  with urea. 
*Denaturant (8 M urea) in lanes 3, 6, 9, and 12 
 
In Figure 3.5, control DNA, 22G0, is in lanes 1-6 and 8-oxoG modified at 
position 1, 22G1, is in lanes 7-12; the protein is p50BD.  The sample types are DNA 
(lanes 1, 7), DNA + p50BD (2, 8), DNA + p50BD denatured (3, 9), DNA + chromium (4, 
10), DNA + p50BD + chromium (5, 11), and DNA + p50BD + chromium denatured (6, 
12).   
For the non-modified strand, if a covalent crosslink formed, it would show in lane 
6 (Figure 3.5, DNA-Protein complex row) with no free oligomer DNA strand (lane 1) as 
covalent crosslinks are typically resistant to denaturing.  If the non-covalent linkages, like 
electrostatic bonding of DNA--protein were subjected to denaturing (lane 3), and were 
not resistant to denaturing, all DNA would show as a DNA only band.  However the 
electrostatic DNA-protein bond remains resistant to denaturing (compare lanes 2 and 3).  
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This resistance to denaturing suggests that the conditions for denaturing are not harsh 
enough to break the hydrogen bonds. 
If a crosslink had formed in the modified strand, it would show up in lane 12 
(DNA-protein complex row, Figure 3.5) with a limited amount, or no, free oligomer 
strand (DNA only row).  The denatured DNA + protein (lane 9) would revert to the DNA 
only lane and not resemble that of to the DNA + protein (lane 8).  The DNA + protein + 
chromium samples (lane 12) would not be affected by denaturing conditions if the bond 
was covalent.  Adding a denaturant, 8 M urea (Figure 3.5), to DNA + protein + 
chromium only slightly disrupts DNA-protein binding in the case of modified DNA.  
Adding heat (50˚C, 10 min) to denature DNA-protein bonds effectively removes the shift 
lane for those samples subjected to denaturing conditions (lanes 3, 6, 9, 12, Figure 3.6). 
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Figure 3.6: Gel comparison of control vs. 8-oxoguanine G1 DNA with and without 
chromium using heat and 8 M urea as a denaturant of p50BD and κB DNA on a 4% 
PAGE gel. 
Lanes 1-6 unmodified DNA, Lanes 7-12 8-oxo G1 DNA 
L R the samples are DNA, DNA + protein, DNA + protein with urea, DNA + 
chromium, DNA + protein + chromium, and DNA + protein + chromium  with urea. 
*Denaturant (8M urea) in lanes 3, 6, 9, and 12 
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In Figure 3.6, the samples are in the same order as Figure 3.5.    The chromium-
free control sample (22G0 + p50BD) appears to be more resistant to heat and urea for the 
non-modified DNA, when comparing DNA bound to p50BD under denaturing conditions 
(lane 3) versus DNA bound to p50BD with chromium under denaturing conditions (lane 
6).  However, for modified DNA, urea (8 M) appears to affect DNA bound to p50BD 
subjected to denaturing conditions with and without chromium (lane 9 versus lane 12) 
similarly.  The denaturing conditions are perhaps too harsh for unmodified DNA and 
DNA 8-oxoguanine modified at position 1 as the denatured hydrogen bonds (lanes 3, 9) 
are not distinctly different than their respective denatured chromium treated DNA-protein 
bonds (lanes 6, 12).  It appears that the arrow indicating the DNA-protein complex row 
for sample 12 is very similar to the DNA-protein complex row for sample 9 which does 
not clearly indicate a DNA-protein crosslinking by chromium. 
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Figure 3.7: Gel of 8-oxoguanine G2 DNA with and without chromium using 8 M urea as 
a denaturant of p50BD and κB DNA. 
Lanes 1-3: DNA (0.26 µM), DNA + hOGG1 + NaCNBH3, DNA + chromium(V)-Salen 
Lanes 4-9: DNA + p50BD (800 ng) + chromium(V)-Salen (0, 0.26, 0.52, 1.3, 2.6, 26 µM) 
+ Urea 
Lanes 10-11: DNA + p50BD + NaCNBH3, DNA + p50BD + chromium + NaCNBH3
On a 6 % DNA retardation gel 
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Figure 3.7 shows 8-oxoguanine modified at position G2 in κB DNA sequence 
bound with protein subjected to chromium oxidation.  Lane 1 is a control lane to 
determine where unbound modified DNA travels on the gel.  Lane 2 is the modified DNA 
bound to hOGG1 (by borohydride trapping, see the arrow indicating bound DNA, Figure 
3.7).  The hOGG1 enzyme has N-glycosylase and AP-lyase activity.8  The hOGG1 
enzyme can be reductively trapped on DNA with addition of NaCNBH3 through the 
reduction of the Schiff base intermediate formed from lysine 44.9,10  The use of 
reductively-trapped DNA—protein is a tool to determine if oxidatively-trapped DNA—
protein (crosslinks) can be visualized on this type of gel.  Due to the higher percentage of 
acrylamide for the gel in Figure 3.7 (6 %), a small amount of the radiolabeled DNA-
protein treated with chromium or NaCNBH3 stayed in the wells (lanes 4-11).  Unlike the 
samples injected into the HPLC, the chromium was not removed from the samples before 
running the gel and has a tendency to block DNA-protein migration into the gel.  In 
Figure 3.7, lane 3 is a control lane with DNA oxidized by chromium.  Lanes 4 through 9 
show DNA bound to p50BD protein subjected to increasing amounts of chromium.  
There is no discernable crosslink which would result in a shift visible on the gel.  Lane 
10, with DNA, p50BD protein, and using NaCNBH3 as a reductant, gives a higher 
molecular weight complex than the DNA-p50BD + Cr(V)-Salen band (lanes 4-9).  It is 
proposed that this corresponds to the formation of a p50BD homodimer bound to the κB 
DNA sequence as seen in Figure 2.11, page 39.  Lane 11, where DNA is bound to 
protein, exposed to chromium, and subjected to NaCNBH3 reductant for crosslinking, 
shows that the monomeric protein binding to DNA is restored (versus lane 10). 
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Figure 3.8: Gel of 8-oxoguanine G3 DNA with and without chromium using 8M urea 
and heat as a denaturant of p50BD and κB DNA 
Lanes 1-2: DNA (0.26 µM), DNA + chromium(V)-Salen,  
Lanes 3-4: DNA + p50BD (2500 ng), DNA + p50BD denatured (urea) 
Lane 5: DNA + p50BD + chromium(V)-Salen,  
Lane 6: DNA + p50BD + chromium(V)-Salen + urea,  
Lane 7: DNA + p50BD + chromium(V)-Salen + urea (30 minute exposure),  
Lane 8-9: DNA + p50BD + chromium(V)-Salen + 30˚C 5 min,  Same with 60˚ C 5 min 
Lane 10: DNA + p50BD + chromium(V)-Salen + urea + 30˚ C heat. 
On a 4% urea gel 
The p50BD protein has been shown to have poor binding to κB DNA when 8-
oxoguanine modifies position 3 (see Figure 2.12, page 40).  Figure 3.8 shows the binding 
of this G3 modified κB DNA (22G3) with p50BD, exposed to chromium and denaturing 
conditions.  DNA bound to protein binds almost the same whether it is subjected to 8 M 
urea denaturing conditions (lane 4) or not (lane 3).  Adding chromium and urea to the 
DNA-protein binding has little impact (lanes 5-7).  However adding heat as a denaturant 
to the DNA-protein binding has great impact; even a gentle heat, 30˚C, completely 
abolishes any binding (lane 8).  This is consistent with the overall weaker binding of 
p50BD to DNA 8-oxoguanine modified at this position. 
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Discussion 
The samples run on the HPLC to detect DNA-protein crosslinking did not confirm 
or refute the presence of crosslinking.  What was seen in Figure 3.4 was that the HPLC 
traces containing DNA with and without p50BD protein and chromium were similar.  
The two traces of DNA and chromium, one with and one without p50BD protein were 
similar, probably due to the ratio of DNA to chromium (1:1).  It was thought that the ratio 
of 1:1 would be sufficient to see a difference between the samples.  A higher amount of 
chromium to DNA would improve the resolution of the Gh/Ia and Sp peaks as seen in 
Figure 3.3.  Earlier HPLC traces agreed with previous work that the p50BD protein 
shielded the DNA from the oxidative effects of chromium (data not shown).  
Nonetheless, a peak for the 8-oxoguanine DNA was determined to have eluted at the 
same time for all traces (8.4 minutes).  Parts of the solution, including any residual buffer 
salt from the cation exchange column, elute quickly.  Specifically, these peaks were seen 
at 1.5 to 2.5 minutes. 
It is possible that there was not enough protein to successfully bind the κB DNA 
or that running the DNA-p50BD protein complex through the cation exchange column 
disrupted some protein hydrogen bonds.  The amount used was sufficient to cause a 
100% DNA shift.  Gel systems with 5’-32P radiolabeled double-stranded DNA can use a 
much smaller amount of DNA to visualize interactions and there is no cation exchange 
column requirement.  On the HPLC, a small amount of protein will certainly bind the 
DNA, yet an insufficient amount of protein might not clearly show the DNA-protein 
complex shifted to a different retention time.  This four-sample HPLC determination of 
DNA-protein crosslinking was run earlier using a solution buffer with DTT and a higher 
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ratio of chromium to DNA (1000:1) where the shielding effects of the protein were 
visible by HPLC trace (data not shown).  Figure 3.4 had no DTT in the sample 
preparation; this last HPLC trace assumed that the DTT of 2.5 mM reduced the 
chromium(V)-Salen (0.5 mM).  It was determined that the HPLC separation based on 
charge was not the correct system for visualizing DNA-protein crosslinks.  
Modified 22-mer DNA and p50BD protein together are quite sizable (13.5KDa 
and 42.4 KDa respectively) which can be a problem when using an older HPLC column.  
Charge separation was not conclusive; thus a gel system was a better choice to determine 
covalent crosslinking for whole protein—DNA.  The benefits include a smaller 
concentration of DNA can be radiolabeled with 32P-γ-ATP and still be visualized, and 
there is no cation exchange column DNA loss as there is no clean-up required to remove 
excess chromium for samples run on a gel. 
 For Figure 3.5, for unmodified DNA, lanes 1-6, the gel implies that chromium 
oxidation could cause covalent crosslinking, but more harsh denaturing conditions are 
required to prove the crosslinking.  The non-modified DNA bound to protein and 
subjected to chromium and denaturing conditions (lane 6) appears more resistant to 
denaturing than DNA bound to protein and subjected to denaturing conditions (lane 3) as 
determined by the amount of unbound DNA (see free DNA arrow).  This result does 
support the theory that a covalent bond is more resistant to degradation than an 
electrostatic bond for DNA-protein crosslinking. 
 In Figure 3.5, for 8-oxoguanine modified at position G1 DNA implies that the 
bond is not covalent when bound to p50BD protein and exposed to chromium.  It seems 
that DNA–protein  subjected to chromium and denaturing conditions (lane 12) appears 
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less resistant to denaturing to denaturing than DNA bound to protein and subjected to 
denaturing conditions (lane 9). This implies that there was no covalent linkage of 
modified DNA with p50BD protein and that the chromium was able to oxidize either the 
DNA or the protein and decrease the electrostatic bonding of the DNA and protein as 
evidenced by unbound DNA (see arrow ‘free DNA’ Figure 3.5).  The DNA bound to 
protein subjected to denaturing 8 M urea (lane 9) is less degraded than the sample of 
DNA bound to protein not subjected to 8 M urea (lane 8) which indicates an unusual 
relationship of urea with modified κB DNA and the truncated p50 protein.  It is known 
that the κB DNA is close to B-form DNA and that when the p50 protein binds to it, there 
is only a slight unwinding in the 5’-GGGG-3’ area and a very small bend produced in the 
DNA.  It is possible that the 8-oxoguanine with p50BD protein bound is structurally 
perturbed compared with unmodified κB DNA with p50BD bound, and adding urea to 
the system disrupts non-specific protein binding, permitting the DNA to adopt a more B-
form shape, which allows for the protein to bind tighter to the DNA.  The bound DNA-
protein complex bands remaining for the urea treated lanes, 3, 6, 9, and 12 suggests that 
the denaturing conditions are not strong enough to break hydrogen bonds. 
 Increasing the denaturing by using mild heat had a drastic effect on the denatured 
samples (Figure 3.6).  For the unmodified DNA, it appeared that DNA bound to protein 
exposed to chromium (lanes 6) was denatured more than the DNA bound to protein 
(lanes 3), in direct contrast to what was seen in Figure 3.5.  For 8-oxoguanine modified 
DNA, the effects of denaturing the DNA-protein complexes with and without chromium 
exposure were essentially the same (lanes 9 compared to 12) which was slightly different 
from the pattern seen in Figure 3.5.  The 8-oxoguanine G1 DNA incubated with protein 
 75
and exposed to chromium and urea/heat had similar amounts of residual binding as well 
as free (non-protein bound) DNA as the modified DNA incubated with protein and 
exposed to urea/heat.  It is possible that the tighter binding affinity of control DNA, 0.605 
µM, compared to the binding affinity for 8-oxoguanine modified at position G1 DNA, 
1.849 µM, with p50BD protein contributed to the variation of the effects of heat/urea on 
the different κB DNA sequence (see table 2.6, page 49). 
 For κB DNA 8-oxoguanine modified at position G2 bound to p50BD protein 
subjected to chromium oxidation (Figure 3.7), increasing amounts of chromium does not 
appear to covalently link the DNA and the protein.  In lane 10, DNA bound to protein 
and exposed to sodium cyanoborohydride gives the dual banding pattern proposed to be 
the p50BD homodimer seen in the EMSA, Figure 2.11, page 39.  It is possible that the 
NaCNBH3 reduced some of the p50BD protein strand and altered the binding of the 
monomeric protein to DNA. The sample ‘DNA + p50BD + chromium + NaCNBH3’ 
mimicked the binding of the DNA-protein bands.  It was seen earlier that as the amount 
of p50BD protein increased past a certain concentration of protein (2.356 µM), the 
p50BD began to bind as a proposed dimer.  This could indicate that at higher amounts of 
truncated p50 protein allosteric cooperative binding is possible.  Without a crystal 
structure of the truncated form of the p50 protein, it is difficult to determine the exact 
effects of truncating the protein.  It is possible that the amino acid residues not included 
stabilized the full p50 protein at the dimerization interface, which is in the C-terminal 
domain and has six variable loops. 
 When using κB DNA 8-oxoguanine modified at position G3, it was seen that 
chromium and urea have little impact on binding of DNA and p50BD protein (Figure 3.9, 
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lanes 4-7).  The binding of the p50 was poor, regardless of any sample additions such as 
chromium and urea.  Adding heat as a denaturant was detrimental to binding; all samples 
subjected to heat had no protein bound lane (Figure 3.9, lanes 8-10), as expected. 
 Taken together, these results indicate that no apparent covalent crosslinking 
occurs with unmodified κB DNA and p50BD protein when subjected to chromium as an 
oxidant.  Furthermore, the above results indicate that 8-oxoguanine-modified at positions 
G1 through G4 κB DNA sequences also do not covalently crosslink to p50BD protein. 
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